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Figure	60	 	 	Snapshot	of	 the	AB	pocket	simulations	of	SIRT1,	SIRT3	and	SIRT5,	after	500ns	of	simulation	
time.	Protein	surface	is	represented	in	grey	and	substrate	and	co-substrate	as	sticks.	Carbon	atoms	are	coloured	in	wheat,	oxygen	in	red,	nitrogen	atoms	in	blue,	phosphates	in	orange,	sulfur	in	yellow	and	hydrogens	in	white.			
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Additionally,	analysis	of	the	RMSD	values	(Figure	61)	showed	a	tendency	for	lower	values	in	SIRT1/NADH	and	SIRT5/NADH	systems.	These	values	suggest	NADH	to	be	more	stable	in	the	AC	 conformation	 than	 its	 oxidised	 counterpart	 NAD+.	 In	 the	 case	 of	 SIRT3	 however,	 the	opposite	 is	 observed.	 Although	 the	 dinucleotide	 stays	 in	 the	 pocket	 throughout	 the	 whole	simulation	time,	the	much	higher	RMSD	values	indicate	a	less	favourable	pose	for	NADH.		
	
Figure	61	 	 	RMSD	values,	for	the	protein,	over	the	500ns	of	simulation	time.	The	protein	backbone	is	represented	as	the	blue	line,	the	ligand’s	position	with	relation	to	(wrt)	the	protein	is	shown	in	red,	and	the	ligand	RMSD	is	in	green.		
3.2 Conclusion	Based	 on	 previous	 studies,	 two	 mechanisms	 for	 sirtuin	 inhibition	 were	 expected:	 a	competitive	 inhibition	with	 regard	 to	NAD+	and	uncompetitive	 to	 the	 substrate	 if	 the	 latter	were	 to	 bind	 to	 the	 sirtuin	 first236,237;	 or	 a	 non-competitive	 inhibition	 to	 the	 substrate	 and	competitive	to	NAD+	in	case	the	two	molecules	bound	to	the	sirtuin	in	a	random	order239.	Yet,	the	 experimental	 results231	 behind	 the	 study	 reported	 in	 this	 chapter	 indicated	 a	 non-
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competitive	inhibition	mechanism	for	both	peptide	substrate	and	NAD+	for	SIRT1	and	SIRT5.	Due	 to	 this	 surprising	 result,	 I	 performed	molecular	 dynamics	 simulations	 on	 the	 enzyme	complexes	 to	 shed	 light	 on	 the	 inhibition	 mechanism	 of	 NADH.	 SIRT1,	 3	 and	 5	 were	complexed	with	a	peptide	substrate	and	NAD+	or	NADH,	which	were	then	positioned	 in	the	AC	or	AB	conformation	 to	 test	both	competitive	and	non-competitive	 inhibition	hypothesis,	respectively.	Analysis	of	 the	“AC	simulations”	showed	that	NADH	tends	to	move	away	 from	the	C	pocket	when	 in	 complex	 with	 SIRT1	 and	 3,	 and	 the	 RMSD	 values	 indicated	 that	 these	 NADH	complexes	were	more	stable	than	the	NAD+	equivalents.	However,	when	comparing	the	three	NADH	systems,	SIRT3:NADH	presents	the	highest	RMSD	value.	Suggesting	this	might	be	the	less	 favourable	 complex	 and	 supporting	 the	 experimental	 results	 that	 showed	 better	inhibition	 of	 SIRT1	 and	 5	 by	 NADH.	 Subsequent	 analysis	 of	 the	 protein	 dinucleotide	interactions	 and	 amide	 bond	 rotation	 provided	 an	 explanation	 for	 the	 finding:	 the	misalignment	between	the	amide	group	from	NADH	and	the	conserved	residues	Ile	and	Asp	in	SIRT3,	prevents	the	hydrogen	bonds	from	establishing	and	decreases	the	binding	affinity	of	 NADH	 to	 SIRT3,	 likely	 due	 to	 the	 “conjugated	 diene	 effect”	 in	 the	 NADH	 amide	 group.	However,	 in	 SIRT5	 this	 effect	 is	 diminished	 by	 the	 interactions	 with	 Ile	 and	 Asp.	 These	findings	indicate	a	major	structural	difference	between	these	enzymes,	which	might	promote	preferential	 binding	 of	 NADH,	 providing	 a	 potential	 molecular	 basis	 for	 differentiation	between	 the	 two	 dinucleotides	 and	 specific	 sirtuins.	 The	AB	 simulations	 showed	 a	 general	slight	movement	of	NAD+	nicotinamide	moiety	towards	the	C	pocket,	while	the	NADH	moiety	move	 further	 away	 from	 the	 B	 pocket	 and	 towards	 the	 enzyme	 surface.	 Similarly	 to	 the	previous	simulations,	the	RMSD	values	also	showed	a	tendency	for	lower	values	in	SIRT1	and	5	 in	 complex	 with	 NADH.	 These	 findings	 could	 justify	 the	 non-competitive	 inhibition	mechanism	observed	during	the	activity	assays	of	SIRT1	and	5.	These	 findings	 indicate	 the	 binding	 of	 NADH	 and	 inhibition	 mechanism	 depends	 on	 the	sirtuin	 studied,	 suggesting	 this	 is	 not	 as	 linear	 as	 previously	 reported	 but	 rather	 a	 more	complex	 binding	 mechanism.	 However,	 and	 although	 all	 experimentally	 tested	 sirtuin	deacylase	activities	showed	some	degree	of	sensitivity	to	NADH,	the	assay	concentrations	of	NADH	were	much	higher	than	the	physiological	ones,	proving	that	NADH	is	unlikely	to	inhibit	sirtuins	in	vivo.	Despite	this,	sirtuins	still	require	NAD+	binding	for	deacylation	and	changes	in	the	NAD+/NADH	ratio	are	known	to	affect	several	cellular	mechanisms,	leading	to	changes	in	sirtuin	activity	and	protein	acylation	in	an	indirect	manner.	
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Computational	chemistry	is	a	field	still	in	development	and	the	prediction	of	binding	affinities	for	 protein-ligand	 complexes	 comprises	 some	 inaccuracies.	 However,	 our	 study	 of	 the	dynamics	of	sirtuin:NAD+(H):substrate	complexes	and	the	differences	observed	between	the	enzymes	may	prove	useful	in	the	design	of	inhibitor	with	improved	selectivity.				
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4. Insights	into	the	structure	of	sirtuin	7	To	 this	 day,	 several	 studies	 have	 been	 performed	 and	 crystallographic	 data	 has	 been	published	 for	 five	 of	 the	 seven	 enzymes.	 However,	 SIRT7	 is	 still	 the	 least	 understood	 and,	with	no	crystallographic	data	available,	 investigating	 this	enzyme	becomes	an	even	greater	challenge.	A	recent	study	from	Hening	Lin240	showed	that	SIRT7	requires	DNA	activation	to	hydrolyze	 acetyl	 groups	 from	 lysine	 residues	 on	 histone	 peptides.	 Moreover,	 in	 the	 same	study	they	demonstrate	that	both	N-	and	C-	termini	are	essential	for	the	enzyme	activity.	In	this	in	silico	study,	we	report	the	first	homology	model	of	SIRT7.		
4.1 Introduction	Sirtuins	are	NAD+-dependent	deacylase	enzymes	known	to	play	major	roles	in	the	chromatin	organization	 and	 in	 the	 molecular	 response	 to	 metabolic	 stress	 and	 cellular	 homeostasis	alterations.	The	mammalian	 sirtuins	have	distinct	biological	 functions,	 expression	patterns,	enzymatic	 activities	 and	 substrate	 specificity105.	 To	 this	 day,	 several	 studies	 have	 been	performed	 for	 five	 of	 the	 seven	human	 sirtuin	 enzymes.	 SIRT7	 is	 still	 the	 least	 understood	however,	 several	 features	 present	 suggest	 its	 participation	 in	 cellular	 processes	 related	 to	human	disease	and	cancer	in	particular.		SIRT7	 has	 been	 shown	 to	 selectively	 mediate	 deacetylation	 of	 lysine	 18	 on	 histone	 H3	(H3K18ac),	a	very	specific	histone	mark	present	in	25%	of	human	promoters241	and	of	which	hypoacetylation	 is	 associated	with	 highly	malignant	 cancers	 and	 poor	 patient	 prognosis146.	Deacetylation	 of	H3K18ac	 promotes	 formation	 of	 transcriptionally	 repressive	 chromatin	 at	specific	gene	promoters	 linked	 to	 tumour	suppression,	 changing	gene	expression	programs	that	 drive	 cancer	 progression242,243	 (Figure	 62).	 Amongst	 these	 gene	 targets	 is	 the	 ELK4-dependent	 tumour-suppressive	 gene	 network,	 implicated	 in	 prostate	 cancer	 and	 others.	Inactivation	of	SIRT7	in	fibrosarcoma,	osteosarcoma	and	prostate	carcinoma	cell	lines	led	to	hyperacetylation	 of	 H3K18	 and	 consequent	 upregulation	 of	 tumour-suppressive	 gene	expression,	 with	 regression	 of	 oncogenic	 transformation244–246.	 Another	 target	 for	 SIRT7	includes	ribosomal	protein	genes,	which	are	also	 transcriptonal	 targets	 for	 the	oncoprotein	MYC247.	By	repressing	the	expression	of	these	genes,	SIRT7	supresses	endoplasmic	reticulum	(ER)	 stress	 and	 prevents	 fatty	 liver	 disease.	 In	 cancer	 cells	 this	means	 SIRT7	 prevents	 ER	stress-induced	 apoptosis,	 allowing	 cancer	 cell	 survival	 and	 proliferation.	 Because	 of	 the	broad	range	of	gene	expression	pathways	MYC	is	involved	in,	SIRT7	is	likely	to	interact	with	
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many	other	targets	that	 influence	tumour	progression248.	These	 findings	suggest	 that	SIRT7	may	play	a	major	role	in	oncogenic	transformation	and	maintenance	of	epigenetic	patterns	in	cancer	cells,	driving	gene	expression	to	stabilize	the	transformed	phenotype	of	these	cells.		Additionally,	 the	subcellular	 location	of	SIRT7	 in	 the	nucleoli,	 subnuclear	sites	 that	mediate	the	 ribosomal	 RNA	 biogenesis	 and	 have	 been	 shown	 to	 increase	 in	 size	 and	 number	 in	aggressive	 tumours249,	 is	 in	 line	 with	 its	 role	 promoting	 protein	 translation	 and	 ribosome	biogenesis	(Figure	63).	Recent	studies	showed	that	SIRT7	deacetylates	the	PAF53	subunit	of	RNA	 polymerase	 I	 (Pol	 I)	 and	 facilitates	 the	 recruitment	 of	 the	 polymerase	 to	 the	 rDNA	promoter	region	and	coding	region,	restoring	ribosomal	RNA	(rRNA)	transcription250.	SIRT7	has	 also	 been	 shown	 to	 interact	 with	 TFIIIC2	 and	 mTOR,	 which	 regulate	 RNA	 Pol	 III	 and	consequent	 transfer	 RNA	 (tRNA)	 transcription	 and	 protein	 synthesis.	 Increased	 levels	 of	ribosome	 biogenesis	 promote	 cancer	 cells	 proliferation	 and	 survival.	 Moreover,	 SIRT7	 is	thought	to	deacetylate	the	tumour-suppressor	p53,	which	would	result	is	cancer	cell	survival	and	proliferation.	However,	the	molecular	mechanisms	involved	are	still	unclear	and	the	data	lacks	additional	confirmation251.	
	
	
Figure	62	 	 	 Effect	 of	 SIRT7	on	 chromatin-dependent	 gene	 expression.	SIRT7	represses	gene	expression	by	deacetylating	 H3K18;	 stabilises	 cancer	 cell	 phenotypes	 through	 repression	 of	 ELK4-dependent	 tumour-suppressor	 genes	 expression;	 and	 decreases	 ER	 stress	 by	 repressing	Myc-dependent	 ribosomal	 protein	 genes.	Image	adapted	from	Paredes,	S.	et	al.	252	
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Figure	63	 	 	Effect	of	SIRT7	on	ribosome	biogenesis	and	protein	synthesis.	 	 In	cancer	cells,	SIRT7	promotes	ribosome	biogenesis	 and	 increased	protein	 synthesis,	 resulting	 in	 cell	 growth	 and	proliferation.	 Image	 adapted	from	Paredes,	S.	et	al.252	
 Despite	all	the	studies	reporting	SIRT7	activity	and	biological	functions,	in	vitro	screening	of	substrates	and	inhibitors	for	SIRT7	still	poses	a	great	challenge.	Current	biochemical	assays	like	 high	 pressure	 liquid	 chromatography	 (HPLC)	 based	 assays	 using	 peptide	 substrates,	cannot	efficiently	measure	and	quantify	the	deacetylase	activity	of	the	commercially	available	SIRT7	(Figure	64).	
	
Figure	 64	 	 	 SIRT7	 deacylation	 activity	 in	 presence	 and	 absence	 of	 nucleic	 acids.	 The	 activity	 of	 the	commercial	SIRT7	was	measured	for	different	N-acyllysine	substrates.		
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To	 the	best	of	my	knowledge,	 the	 recent	 study	 from	Hening	Lin	and	co-workers240	was	 the	first	 study	 to	 report	 reliable	 enzymatic	 activity	 for	 human	 SIRT7.	 In	 this	 study,	 SIRT7	was	expressed	 and	 purified	 from	 E.	 coli,	 and	 the	 deacetyalse	 activity	 on	 H3K9	 and	 H3K18	substrates	was	measured	trough	HPLC	in	the	absence	or	presence	of	double-stranded	DNA.	Results	 showed	 that	 SIRT7	 requires	DNA	activation	 to	hydrolyze	 acetyl	 groups	 from	 lysine	residues	on	histone	peptides.	Moreover,	both	N-	and	C-	termini	were	essential	for	the	enzyme	activity,	explaining	the	role	of	SIRT7	as	a	regulator	of	transcription.	As	SIRT7	has	also	been	shown	to	regulate	rRNA	gene	transcription,	ribosome	biogenesis	and	protein	synthesis,	another	study	from	the	same	group253	tested	both	deacetylase	and	defatty-acylase	activities	of	SIRT7	on	H3K9	and	H3K18	based	peptides	with	different	nucleic	acids.	Similarly	to	the	previous	study,	neither	activity	was	detected	in	the	absence	of	nucleic	acids.	Deacetylation	 of	 H3K18ac	 was	 detected	 in	 the	 presence	 of	 either	 DNA	 or	 RNA,	 while	deacylase	of	H3K9	butyryl,	octanoyl	and	myristoyl	substrates	was	detected	in	the	presence	of	tRNA.	Myristoyl	was	the	most	efficient	deacylase	reaction,	which	suggests	a	link	between	the	substrate	specificity	of	SIRT6	and	SIRT7254.	Furthermore,	assays	with	the	full-length	enzyme	and	 the	 truncation	mutants	 of	 SIRT7	 showed	 that	 both	 termini	 interact	with	 RNA	 and	 are	essential	for	the	catalytic	activities	of	SIRT7. Although	the	findings	from	these	two	studies	provide	proof	of	an	in	vitro	assay	able	to	detect	SIRT7	 activity,	 this	 is	 still	 the	 least	 understood	 sirtuin	 and,	 with	 no	 crystallographic	 data	available,	 investigating	 this	 enzyme	 is	 a	 challenge.	 Computational	 structure	 prediction	methods	 provide	 important	 structural	 information	 that	 may	 be	 used	 in	 the	 study	 of	 the	protein	function,	dynamics	and	ligand	interactions.	These	methods	refer	to	the	inference	of	a	three-dimensional	(3D)	structure	of	a	protein	based	on	its	one-dimensional	(1D)	amino	acid	sequence	with	 reasonable	accuracy.	Depending	on	 the	 target	protein	 there	are	 three	major	approaches	 to	 3D	 structure	 prediction,	 ab	 initio	 (or	 de	 novo	 design),	 fold	 recognition,	 and	homology	(or	comparative)	modeling.	Ab	initio	methods	rely	only	on	algorithms	and	not	on	any	 existing	 structural	 data	 therefore	 requiring	 extensive	 computational	 resources.	 Due	 to	the	costs,	these	methods	are	mostly	carried	out	for	relatively	small	proteins.	Fold	recognition,	also	known	as	protein	 threading,	 is	used	 to	model	proteins	with	no	3D-solved	homologous	but	for	which	sequence-structure	relationships	can	be	found.	Threading	is	based	on	advanced	sequence	comparison	methods,	using	statistics	of	the	structural	relationships	between	all	the	entries	 in	 the	 Protein	 Data	 Bank	 (PDB)	 and	 the	 target	 sequence	 to	 be	modelled.	Meaning,	each	amino	acid	in	the	target	sequence	is	aligned	to	a	position	in	the	template	structure	and	evaluated	as	to	how	well	it	fits,	until	a	favourable	hit	is	found.	Finally,	homology	modelling	is	
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used	when	 there	 is	a	clear	relationship	between	 the	 target	sequence	and	 the	sequence	of	a	3D-solved	 structure,	 usually	 belonging	 to	 the	 same	 family,	 deposited	 in	 the	PDB255,256.	 As	 a	result,	 the	model	of	 the	 target	 sequence	 can	be	built	 from	sequence	 related	 structures	 that	share	 some	 level	 of	 sequence	 similarity.	 Amongst	 the	 three	 approaches,	 this	 is	 the	 most	detailed	and	provides	the	most	reliable	models255.	The	premise	behind	this	method	relies	on	the	fact	that	during	evolution,	the	structure	is	more	conserved	than	the	sequence	itself,	thus	even	 distantly	 related	 sequences	 can	 still	 share	 the	 same	 folds257,258.	 Based	 on	 structures	deposited	in	the	PDB,	Rost259	was	able	to	define	limits	that	serve	as	a	guide	line	for	this	rule.	According	to	the	research,	two	given	sequences	are	more	likely	to	adopt	a	similar	structure	if	the	length	and	percentage	of	identical	residues	fall	in	the	“safe”	region	(Figure	65).		
 
Figure	65			The	two	zones	of	sequence	alignment	defined	by	Rost259.			All	 current	 protocols	 for	 homology	 modelling	 include	 four	 sequential	 steps:	 template(s)	selection,	 target-template	 alignment,	 model	 (backbone	 and	 loops)	 building,	 and	 model	validation.	 The	 first	 step	 in	 this	 process	 is	 to	 identify	 protein	 structures	 to	 be	 used	 as	templates,	 using	 sequence	 comparison	 methods	 or	 sequence-structure	 methods	 know	 as	threading	 methods.	 In	 the	 “safe”	 zone	 defined	 by	 Rost259,	 the	 sequence	 identity	 between	target	 an	 possible	 template	 is	 high	 enough	 to	 be	 detected	 by	 simple	 sequence	 comparison	methods	 like	BLAST260	 (sequence-sequence	 comparison)	 or	 PSI-BLAST261	 (sequence-profile	comparison).	The	main	advantage	of	BLAST	is	its	high	speed	to	find	hits,	while	the	drawback	is	 that	 conserved	 and	 variable	 positions	 are	 treated	with	 the	 same	weight,	 influencing	 the	final	 alignment	 score.	Moreover,	 this	method	cannot	detect	distant	homologs	 just	based	on	sequence	similarity.	PSI-BLAST	on	the	other	hand,	builds	off	 the	alignments	generated	by	a	
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run	of	 the	BLAST	and	generates	a	multiple	alignment	 further	used	 to	calculate	a	profile,	or	position-specific	 score	matrix	 (PSSM).	This	profile	 captures	 the	 conservation	pattern	 in	 the	alignment	and	attributes	higher	scores	to	conserved	positions	and	near-zero	scores	to	weakly	conserved	 positions.	 Additionally,	 because	 this	 is	 an	 iterative	 process	 the	 profile	 describes	not	 only	 the	 target	 sequence	 but	 the	 whole	 family	 of	 homologues,	 allowing	 detection	 of	remote	similarities262.	Another	method	involving	sequence	comparison	is	the	Hidden	Markov	Models	 (HMMs)263.	These	profiles	describe	 the	sequence	variability	of	 the	protein	 family	at	each	 position	 and	 can	 be	 used	 to	 identify	 protein	 domains	 even	 if	 the	 similarity	 is	 very	weak264.	This	method	lacks	initial	filtering	of	a	database,	which	increases	the	sensitivity	of	the	method265.	Threading	methods	have	been	developed	based	on	the	fact	that	sequence	similarity	does	not	necessarily	mean	 structural	 similarity	 –	 protein	with	 similar	 structures	 can	 have	 very	 low	sequence	 identity	–	and	amino	acids	 in	a	protein	exhibit	 interaction	preferences	depending	on	 the	 structural	 environment265.	 	 These	 amino	 acid	 preferences	 can	 be	 calculated	 and	organized	 in	 the	 form	of	a	Nx20	profile,	 similar	 to	 the	one	used	by	PSI-BLAST,	and	used	 to	assess	the	fitness	of	the	sequence	to	the	template	structure.	These	methods	were	developed	with	 the	 goal	 of	 finding	 evolutionary	 distant	 relationships	 with	 less	 than	 30%	 sequence	identity.	 However,	 due	 to	 the	 complexity	 of	 the	 profiles,	 the	 calculation	 of	 the	 fitness	 to	 a	structure	can	 take	hours	and	be	computationally	expensive.	With	 the	 increasing	number	of	structures	 being	 deposited	 in	 the	 databases,	 the	 computational	 requirements	 become	 so	steep	that	the	calculations	can	only	be	run	in	supercomputers.	Once	the	templates	have	been	identified,	 the	target	sequence	needs	to	be	aligned	to	further	build	 the	 3D	 model	 of	 the	 target.	 This	 alignment	 can	 be	 obtained	 by	 aligning	 multiple	templates	 to	 the	 target	 sequence	 using	 CLUSTALW266,267,	 aligning	 the	 target	 sequence	 to	 a	HMMs	 profile	 built	 based	 on	 the	 Pfam	 family	 sequence	 alignment	 using	 HMMER268,	 or	 by	aligning	the	target	sequence	to	a	HMMs	profile	built	from	a	structural	alignment.	Because	the	latter	strategy	takes	into	consideration	both	sequence	similarity	and	structural	information,	this	is	considered	more	trustworthy.	With	 the	 final	 target-template	 alignment,	 the	 3D	model	 can	be	 generated	by	modelling	 the	backbone,	loops	and	side-chains	of	the	protein.	In	this	step,	the	modelling	can	be	carried	out	by	 assembly	 of	 rigid	 bodies	 (the	 aligned	 template	 structures	 are	 dissected	 into	 conserved	core	regions,	variable	loops	and	side	chains	and	then	assembled	by	superposing	in	the	target	model)256,	by	segment	matching	(the	target	sequence	 is	broken	 into	short	segments	 further	used	to	search	databases	for	matching	fragments)269,270,	or	by	satisfaction	of	spatial	restraints	
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(the	templates	alignment	is	used	to	generate	constraints	and	restraints	that	serve	as	guide	to	build	 the	 model	 of	 the	 target	 sequence)271.	 The	 last	 step	 in	 this	 process	 includes	 the	evaluation	of	the	model	quality,	which	determines	the	information	obtained	from	it.	In	order	to	estimate	the	errors	in	the	generated	structure,	we	can	compare	the	model	to	experimental	data	 of	 the	 target	 protein	 and/or	 evaluate	 spatial	 features	 like	 stereochemistry	 through	statistics	of	experimentally	determined	structures.		The	next	subsections	report	the	generation	of	a	3D	model	for	SIRT7,	following	the	steps	here	described.	Possible	bias/errors	and	 the	 strategies	applied	 to	overcome	 them	are	presented	throughout.																				
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4.2 Sequence	analysis	
4.2.1 Protein	alignment	In	order	to	gain	insight	into	the	structure	and	activities	of	SIRT7,	I	first	analysed	the	sequence	and	 phylogeny	 of	 the	 enzyme,	 followed	 by	 its	 predicted	 structural	 features.	 Protein	sequences	for	SIRT1-7	were	obtained	from	Uniprot272	and	aligned	(Figure	66).	
	
Figure	 66	 	 	 Sequence	 alignment	 of	 human	 SIRT1-7.	NAD+-binding	 regions	 are	 highlighted	 in	 grey,	 catalytic	histidine	in	purple	and	Zn2+-binding	cysteines	in	organge.	SIRT7	sequence	is	depicted	in	red.	
Insights	into	the	structure	of	sirtuin	7		_________________________________________________________________________________________________________________________________________________________________________	
	 97	
A	comparison	between	SIRT7	amino	acid	sequence	and	the	other	human	sirtuins	showed	this	enzyme	contains	all	the	required	residues	known	to	participate	in	deacylase	reactions.	In	fact,	SIRT7	 exhibits	 a	 deacylase	 domain	 (residues	 90-331),	which	 is	 divided	 into	 a	 Zn2+-binding	domain	 and	 a	 Rossman-fold	 domain,	 a	 catalytic	 histidine	 (His187),	 four	 Zn2+-binding	cysteines	 (Cys195,	 198,	 225	 and	228),	 and	 a	NAD+-binding	 region	 (residues	 107-126,	 167-170,	268-270,	297-299	and	315).		
4.2.1 Structural	predictions	Next,	I	used	NetSurfP273	to	predict	the	secondary	structure	of	SIRT7	and	compare	it	with	the	other	 known	human	 sirtuins	 (Supplementary	 Figure	 1).	 Observations	 showed	predicted	 α-helices	 and	 β-strands	 of	 the	 catalytic	 domain	 in	 similar	 locations	 to	 SIRT6.	 Moreover,	 the	software	successfully	predicted	α-helices	at	the	N-	and	C-	termini	of	SIRT7	(Figure	67).	These	findings	were	further	supported	by	the	phylogenetic	analysis	of	the	Sir2	family,	which	groups	SIRT6	and	-7	in	the	same	class	IV65,274		
	
Figure	67		 	Secondary	structure	prediction	of	SIRT7	compared	to	SIRT6.	Blue	areas	represent	α-helices	and	green	areas	are	β-strands.	The	position	of	the	conserved	regions	from	Figure	66	are	highligted.				
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4.2.2 Phylogenetic	analysis	and	conservation	To	 identify	 highly	 conserved	 regions	 within	 SIRT7	 that	 could	 differ	 from	 the	 rest	 of	 the	sirtuin	enzymes	and	therefore	be	related	to	its	unique	enzymatic	activity,	I	compared	SIRT7	sequence	 to	 all	 higher	 eukaryote	 sequences	 of	 SIRT1-7.	 Structures	 of	 human	 and	 bacterial	sirtuins	were	 used	 to	 generate	 a	HMM	profile	 to	which	 all	 chordate	 sequences	 of	 SIRT1-7,	available	on	Uniprot,	were	added.	Although	 most	 regions	 of	 SIRT7,	 thought	 to	 participate	 in	 the	 deacylation	 reaction,	 are	efficiently	aligned	with	other	sirtuins,	there	are	several	differences	in	the	alignments	(Figure	68).	The	most	striking	one	is	the	deletion	in	the	sequence	following	the	region	corresponding	to	α3	in	SIRT1	(residues	133-141	in	SIRT7).	 	In	all	previously	solved	sirtuin	structures,	this	segment	constitutes	a	conserved	“cofactor-binding	 loop”	 involved	 in	NAD+	binding	and	that	can	adopt	different	conformations.	SIRT7	seems	to	lack	the	cofactor-binding	loop,	and	instead	align	more	closely	with	SIRT6.	Another	significant	difference	amongst	sirtuins	is	the	length	of	the	sequence	between	the	first	and	second	pairs	of	Zn2+-binding	cysteines,	and	between	the	cysteines	of	the	second	pair.	Similarly	to	SIRT5	and	in	contrast	to	SIRT6,	the	motif	between	pairs	 is	 extended	 by	 five	 amino	 acids	 in	 SIRT7	 (residues	 214-219),	 while	 the	 sequence	segment	 between	 the	 second	 pairs	 of	 cysteines	 (residues	 225-228)	 is	 shorter	 and	 aligns	better	with	SIRT1-3.	 	Moreover,	 the	conserved	FGEXL	 loop	responsible	 form	binding	 to	 the	peptide	substrate	backbone	is	also	present	in	SIRT7	with	a	slightly	different	sequence	FGERG	(residues	 239-243).	 The	 arginine	 and	 glutamic	 acid	 residues	 known	 to	 form	 a	 salt	 bridge,	conserved	on	human	SIRT1-5,	 are	 also	present	 in	 SIRT7	 (Arg233	 and	Glu241).	A	 sequence	comparison	 of	 all	 Uniprot	 chordate	 sequences	 of	 SIRT7	 shows	 a	 high	 global	 sequence	homology	and	a	high	conservation	of	 the	 two	motifs	mentioned	 supra	vide	 (Supplementary	Figure	2).	
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Figure	68			Structure-based	sequence	alignment	of	the	catalytic	core	of	SIRT1-7	and	bacterial	sirtuins.	Due	to	the	length	of	the	alignment,	three	sequences	from	higher	eukaryotes	were	selected	for	each	human	sirtuin.	The	colouring	indicates	conservation	based	on	the	BLOSUM62	score.		Using	the	previous	phylogenetic	analysis	of	more	than	700	sirtuin	sequences	 from	proteins	across	several	species,	I	analysed	relationships	between	classes	of	sirtuins.	This	phylogenetic	tree	 (Figure	 69)	 supports	 the	 previous	 classifications	 based	 on	 sequence	 information	 only	and	groups	SIRT1-3	together	in	class	I,	SIRT4	in	class	II,	SIRT5	in	class	III	and	SIRT6	and	7	in	
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class	 IV.	 The	 subclusters	 comprising	 the	 strong	 deacetylases	 SIRT1-3	 also	 include	 yeast	sirtuin	 deacetylases	 and	 are	 clearly	 separated	 from	 the	 other	 branches.	 This	 indicates	deacylases	might	have	developed	early	in	evolution	and	later	on	diversified	to	target	different	posttranslational	modifications.		
	
Figure	69			Phylogenetic	tree	generated	from	structure-based	alignment	of	human	and	bacterial	sirtuins,	
extended	by	adding	760	sequences	from	higher	eukaryotes.	Varying	shades	of	red	represent	class	I	sirtuins,	green	 is	 class	 II,	 orange	 is	 class	 III,	 shades	 of	 blues	 referres	 to	 class	 IV	 sirtuins	 and	 black	 represents	 bacterial	sirtuins.		To	determine	the	structure	of	SIRT7	and	locate	the	highly	conserved	residues	found,	I	built	a	homology	model	based	on	sequence	similarity	to	other	sirtuins.								
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4.3 Structural	analysis	
4.3.1 Template	selection	The	first	step	in	the	process	of	building	a	homology	model	is	to	find	suitable	templates	that	cover	the	entirety	of	the	target	sequence.	A	search	for	potentially	related	sequences	of	known	structure	was	performed	by	searching	the	Protein	Data	Bank	using	the	full	length	sequence	of	SIRT7	 and	 the	 NCBI	 BLAST	 tool260.	 This	 approach	 was	 only	 able	 to	 retrieve	 templates	covering	the	catalytic	domain	portion	of	the	target	sequence.	A	new	attempt	was	made	using	the	 iterative	 sequence	 comparison	 method	 PSI-BLAST,	 as	 well	 as	 the	 HMM-based	 tool	HHsearch275.	 	 Similarly	 to	 BLAST,	 these	 methods	 found	 templates	 matching	 the	 catalytic	domain	only.	A	summary	of	the	results	is	shown	in	Figure	70.	As	expected,	the	top	hits	in	each	method	include	human	sirtuins	and	Sir2-like	proteins.	When	considering	sequence	similarity	alone	(BLAST)	the	best	templates	include	hSIRT6,	Sir2,	hSIRT3	and	hSIRT2,	in	this	order.		On	the	 other	 hand,	 the	 searches	 using	 profiles	 generated	 from	 multiple	 sequence	 alignments	were	able	to	find	more	similarities	with	all	the	human	sirtuins	and	some	Sir2	homologues.		Because	some	of	the	templates	shared	around	30%	sequence	identity	with	the	target,	which	is	 not	 much	 higher	 than	 the	 25%	 threshold,	 I	 decided	 to	 analyse	 multiple	 templates	simultaneously.	 For	 each	 of	 the	 searching	methods	used,	 a	 template	 from	each	human	 and	bacterial	sirtuin	was	selected.	The	sequence	alignments	can	be	seen	in	Supplemental	Figure	3-9	and	Table	12	summarises	the	results	obtained.		
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Figure	70			Summary	of	the	template	search	using	Blast,	PsiBlast	and	HHsearch.			
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Table	12			Statistics	for	the	top	hits	from	each	method.	Lower	the	E-values	and	gap	percentage,	together	with	higher	identity	and	similarity,	produce	better	templates.	
	When	choosing	 the	best	 template	 for	 the	catalytic	domain,	several	 factors	were	considered,	amongst	them	the	E-value,	the	resolution	and	the	R-factor	for	the	template’s	crystallographic	structure,	the	presence	or	absence	of	ligands	and	substrates,	and	the	phylogenetic	similarity	to	 the	 target.	SIRT6	(PDBID:	3ZG6)254	 template	 found	through	sequence-profile	comparison	(PsiBlast)	has	the	 lowest	E-value,	a	reasonable	resolution	of	2.2Å,	 is	complexed	with	both	a	peptide	substrate	and	an	adenosine-diphosphoribose	molecule,	 and	 is	grouped	 in	 the	same	
Template	 PDBID	 	 E-value	 Identity	(%)	 Similarity	(%)	 Gaps	(%)	
	 	 	 	 	 	 	
SIRT1	 5BTR	 PsiBlast	 1-46	 21	 39	 18	
HH	search	 0	 24	 	 	
	 	 	 	 	 	 	
SIRT2	 4R8M	 Blast	 1-10	 25	 43	 19	3ZGO	 PsiBlast	 2-49	 23	 38	 19	
HH	search	 0	 27	 -	 -	
	 	 	 	 	 	 	
SIRT3	 4BVH	 Blast	 3-11	 29	 44	 17	4JSR	 PsiBlast	 3-52	 25	 38	 15	
HH	search	 0	 29	 -	 -	
	 	 	 	 	 	 	
SIRT5	 3RIY	 PsiBlast	 3-53	 21	 36	 16	
HH	search	 0	 26	 -	 -	
	 	 	 	 	 	 	
SIRT6	 3K35	 Blast	 3-44	 43	 56	 12	3ZG6	 PsiBlast	 3-79	 41	 55	 8	
HH	search	 0	 41	 -	 -	
	 	 	 	 	 	 	
Sir2	
1ICI	 PsiBlast	 4-64	 26	 40	 13	1Q17	 PsiBlast	 2-47	 23	 39	 16	1S5P	 PsiBlast	 6-43	 23	 38	 20	1S7G	 PsiBlast	 3-68	 28	 44	 12	2H59	 PsiBlast	 9-65	 30	 44	 13	3U31	 PsiBlast	 2-47	 23	 42	 12	5A3A	 HH	search	 2-43	 16	 -	 -	
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phylogenetic	class	IV	as	SIRT7.	This	made	SIRT6	the	most	appropriate	template	to	model	the	catalytic	core	of	SIRT7.	The	template	of	SIRT6	found	by	sequence	comparison	(PDBID:	3K35)	was	used	as	comparison	due	to	the	high	identity	to	the	target.	Because	previous	attempts	to	find	templates	with	the	full	length	target	sequence	resulted	in	lack	of	termini	templates,	I	divided	the	sequence	into	three	domains	(C-terminal,	N-terminal	and	catalytic	domain)	and	ran	the	template	search	for	the	termini	separately.	Earlier	this	year,	Priyanka	and	colleagues276	were	able	to	crystallise	the	N-terminal	domain	of	human	SIRT7	by	expression	and	purification	of	the	fusion	protein	MBP-SIRT7NTD.	In	the	study	reported,	the	N-terminal	consists	of	three	helices,	the	longest	α1	and	two	short	ones	α2	and	α3	lying	perpendicularly.	This	structure	(PDBID:	5IQZ)276	was	therefore	used	as	template	for	the	N-terminal	sequence	domain	of	SIRT7.	On	the	other,	and	since	the	BlastP®	search	resulted	in	 zero	 templates	 for	 the	 C-terminal	 of	 SIRT7,	 I	 tried	 a	 PsiBlast	 search	 based	 on	 the	conservation	 information	of	 several	 related	sequences.	This	approach	allows	 the	search	 for	distant	 homologues	 and	 resulted	 in	 one	match,	 Yeast	 Enolase	 1	 (PDBID:	 2XH2)277.	 The	 3D	structure	of	this	template	was	in	good	agreement	with	the	α-helices	predicted	by	NetSurfP273	for	the	C-terminal.		
4.3.2 Target-Template	alignment	Two	different	alignments	were	built	using	align2d()	command	in	MODELLER278	and	edited	with	 Jalview279,	 one	 with	 the	 three	 templates	 PDBID:	 5IQZ,	 3ZG6	 and	 2XH2,	 and	 another	where	3ZG6	was	replaced	with	3K35.	Align2d()	is	based	on	a	dynamic	algorithm280	and	takes	into	 account	 structural	 information	 from	 the	 templates.	 This	 algorithm	 optimises	 gap	placement	 to	 solvent	 exposed	 regions,	 outside	 predicted	 α-helices	 and	 β-strands.	 The	accuracy	 of	 the	 alignment	 is	 essential	 for	 the	 quality	 and	 usefulness	 of	 the	 model.	 This	technique	 reduces	 alignment	 errors	 and	 is	 most	 important	 with	 low	 similarity	 sequences	(below	 30%).	 These	 approaches	 were	 combined	 to	 generate	 the	 multiple	 sequence	alignments	shown	in	Figure	71	and	Figure	72.	The	templates	showed	100%	and	38%	identity	with	the	target,	for	the	N-terminal	and	C-terminal,	and	41%	and	43%	for	the	catalytic	domain	of	3ZG6	and	3K35,	respectively.	
Insights	into	the	structure	of	sirtuin	7		_________________________________________________________________________________________________________________________________________________________________________	
	 105	
	
Figure	71			Alignment	between	SIRT7	target	sequence	and	template	sequences	from	5IQZ,	3ZG6	and	2XH2,	
in	fasta	format.	Colour	scheme	as	in	Figure	66.		
	
Figure	72			Alignment	between	SIRT7	target	sequence	and	template	sequences	from	5IQZ,	3K35	and	2XH2,	
in	fasta	format.	Colour	scheme	as	in	Figure	66.		
4.3.3 Model	building	Once	the	target-template	alignment	is	constructed,	MODELLER	can	be	employed	to	build	a	3D	structure	using	comparative	modelling.	In	this	case,	to	assess	the	structural	differences	that	varying	 alignments	 and	 templates	 could	 cause	 on	 the	 SIRT7	 model,	 the	 alignments	 from	Supplementary	Figure	3-9	were	used	to	build	several	models	for	SIRT7	as	in	Figure	73.		
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Figure	 73	 	 	 Models	 of	 SIRT7	 obtained	 from	 Supplementary	 Figure	 3-9,	 using	 MODELLER.	 Protein	 is	represented	as	cartoon,	Zn2+	as	sphere	and	ligands	as	sticks.	Structures	in	green,	cyan	and	magenta	correspond	to	models	 based	 on	 Blast,	 PsiBlast	 and	 HHsearch	 alignments,	 respectively.	 A.	 SIRT1	 template	 models;	 B.	 SIRT2	template	models;	C.	SIRT3	template	models;	D.	SIRT5	template	models;	E.	SIRT6	template	models;	F.	Bacterial	Sir2	template	models	obtained	from	PsiBlast	alignments	only.		In	 general,	 all	models	 show	 the	 typical	 sirtuin	 architecture	with	 the	 Rossman-fold	 domain	and	a	Zinc-binding	domain,	and	there	is	a	clear	overlap	of	the	Rossman-fold	domains	in	all	the	models.	 The	major	 differences	 are	 present	 in	 the	 Zn2+-binding	 domain	 and	 in	 the	 cofactor-binding	 loop,	 two	 structures	 essential	 to	 the	 protein	 stability	 and	 substrate	 binding.	When	comparing	 alignments,	 deviations	 were	 smaller	 between	 PsiBlast	 and	 HMM	 alignments	(Supplementary	 Table	 1-2).	 This	 means	 using	 structure	 aware	 alignments	 with	 higher	similarity	to	the	target	sequence	produced	models	with	 less	deviations	and,	 therefore	more	consistent.	10000	models	were	built	for	the	target	sequence	and	all	of	them	were	evaluated	
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with	 the	 discrete	 optimised	 protein	 energy	 (DOPE)	 potential	 in	 MODELLER.	 DOPE	assessment	 score	 is	 a	 relative	 measure	 used	 to	 rank	 models	 generated	 from	 the	 same	alignment	and	the	lower	the	score,	the	better	the	model.	The	figures	below	show	the	“best”	models	 of	 SIRT7,	 using	 3ZG6	 (Figure	 74	 –	 Model	 A)	 and	 3K35	 (Figure	 75	 –	 Model	 B)	 as	templates.	The	global	DOPE	scores	are	-31704.471	and	-32595.633,	respectively.	
	
Figure	74			MODELLER	model	for	SIRT7	using	3ZG6	as	template	for	the	catalytic	domain.	Zn2+	is	represented	as	sphere	(grey)	and	 ligand	APR	as	sticks	 (carbons	 in	cyan).	Catalytic	domain	 is	shown	 is	yellow	and	N-	and	C-termini	in	green.	NAD+-binding	regions	are	coloured	in	dark	grey,	 	Zn2+-binding	cysteines	and	catalytic	histidine	are	represented	as	sticks	with	orange	and	magenta	carbons,	respectively.		
A	
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Figure	75			MODELLER	model	for	SIRT7	using	3K35	as	template	for	the	catalytic	domain.	Zn2+	is	represented	as	sphere	(grey)	and	 ligand	APR	as	sticks	 (carbons	 in	cyan).	Catalytic	domain	 is	shown	 is	yellow	and	N-	and	C-termini	 in	green.	NAD+-binding	regions	are	coloured	in	dark	grey,	 	Zn2+-binding	cysteines	and	catalytic	histidine	are	represented	as	sticks	with	orange	and	magenta	carbons,	respectively.		The	overall	 structure	of	 the	 sirtuin	 catalytic	domain	 is	maintained	 in	both	models,	with	 an	almost	 perfect	 overlap:	 a	 Rossman-fold	 domain	 and	 a	 Zn2+-binding	 domain	 with	 four	cysteines	coordinating	the	zinc	ion;	the	active-site	is	located	in	between	them,	harbouring	the	peptide	substrate	and	the	dinucleotide	positioned	above	the	six-strand	β-sheet.	The	catalytic	histidine	 is	 positioned	 just	 below	 the	 lysine	modification	 of	 the	 substrate	 in	 Model	 A	 and	oriented	 towards	 the	 dinucleotide	 ribose.	 Due	 to	 the	 sequence	 deletion	 at	 the	 cofactor-binding	 loop,	 SIRT7	 catalytic	 core	 assumes	 a	more	 “open”	 conformation,	 similar	 to	 SIRT6,	with	surrounded	by	hydrophobic	residues.	This	indicates	the	wide	cleft	could	accommodate	
B	
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long-chain	 substrates	 like	 myristoyllysine.	 Due	 to	 the	 use	 of	 a	 template	 in	 the	 “closed”	conformation	after	nucleotide	binding,	specific	features	of	this	state	were	also	modelled	onto	SIRT7	structure.	For	example,	the	conserved	Phe/Tyr	(Tyr119)	of	the	cofactor-binding	loop	is	 positioned	 on	 top	 of	 the	 ADP	 ribose.	 In	 the	 model,	 the	 Arg233	 side	 chain,	 which	 I	hypothesise	 to	 be	 involved	 in	 the	 sirtuin	 conserved	 salt	 bridge,	 is	 oriented	 towards	 the	protein	 surface	 instead	of	 the	Rossman	 fold.	 	 This	 could	be	due	 to	 errors	 in	 the	 side	 chain	packing	and	refinement	through	molecular	dynamics	could	surmount	the	problem281.	The	most	striking	difference	between	the	two	models	is	the	positioning	of	the	termini.	While	the	secondary	structure	of	both	termini	is	identical	between	models,	the	loops	connecting	the	catalytic	domain	and	each	 terminal	 are	unexpectedly	distinct.	 For	 this	 reason,	both	models	were	 further	 evaluated	 to	 assess	 which	 template	 produced	 the	 best	 quality	 model.	Additionally,	 bioinformatics	 analysis	 with	 Profunc	 server282	 provided	 two	 hits	 for	 DNA-binding	 templates	 for	 the	 N-terminal,	 transcription	 factors	 E2-alpha	 (PDBID:	 2QL2)283	 and	Mad-Max	 (PDBID:	 1NLW)284.	 These	 proteins	 are	 known	 to	 bind	 DNA	 on	 E-box	 motifs	(CAXXTG),	 thus	supporting	the	hypothesis	of	SIRT7	binding	DNA.	Although	no	DNA-binding	templates	 were	 identified	 for	 the	 C-terminal,	 a	 structural	 similarity	 based	 search	 using	PDBeFOLD285	and	the	modelled	SIRT7	C-terminal	region,	resulted	in	three	hits,	the	two	with	higher	 sequence	 identity	 corresponding	 to	 DNA-binding	 domains	 (PDBID:	 1Q1V286	 and	2LK2),	which	also	supports	the	hypothesis.		
4.3.4 Model	evaluation	The	last	step	in	the	homology	modelling	process	is	the	evaluation	of	the	model.	After	one	or	more	 models	 are	 selected	 as	 final,	 enclosed	 errors	 need	 to	 be	 detected	 in	 order	 to	discriminate	whether	 they	 affect	 structural	 or	 functional	 regions	 of	 the	 protein.	 There	 are	two	 approaches	 to	 the	 subject.	 The	 first	 relies	 on	 the	 information	 available	 for	 the	 target	sequence	and,	although	it	does	not	ensure	the	correctness	of	the	model,	 inconsistencies	are	reason	 enough	 for	 dismissal	 of	 the	model.	 The	 second	 approach	 consists	 of	 evaluating	 the	stereochemistry	 of	 the	 model	 and	 other	 spatial	 features,	 like	 packing,	 position	 of	 the	hydrophobic	 core,	 residue	 solvent	 accessibility,	 spatial	 distribution	 of	 charged	 groups	 and	main-chain	hydrogen	bonding	structures287.		Regarding	the	first	approach,	secondary	structure	regions	conserved	across	the	sirtuin	family	have	 also	been	 correctly	 identified	 in	 the	 two	 SIRT7	models,	 as	mentioned	 in	 the	previous	section.	 Similarly,	 protein	 residues	 essential	 for	 deacylation,	 such	 as	 the	 catalytic	 histidine	
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and	the	C	pocket	cysteine	and	aspartate,	are	positioned	properly	in	relation	to	the	substrate	and	cofactor.	The	models	were	further	evaluated	through	stereochemistry	analysis	using	PROCHECK288.	A	summary	of	the	computed	stereochemical	parameters	for	the	main	chains	is	shown	in	Figure	76	and	Figure	77.	The	values	from	the	models	are	compared	with	well-refined	structures	at	a	similar	 resolution.	 All	 the	 values	 are	 within	 the	 typical	 values,	 indicating	 a	 good	 quality	model.	However,	a	comparison	between	the	values	for	each	model	show	better	results	for	the	Model	B	with	a	higher	percentage	of	residues	in	the	most	favourable	conformation	(90.3%	vs	87.6),	higher	G-factor	(-0.1	vs	-0.4)	and	lower	bad	contacts	ratio(4.5/5.1).	
	
	
Figure	76			Summary	of	the	computed	stereochemical	parameters	for	residues	main-chain	of	Model	A.	All	the	values	are	within	the	typical	values,	indicating	good	stereochemistry	quality	for	the	model.		
	
Figure	77			Summary	of	the	computed	stereochemical	parameters	for	residues	main-chain	of	Model	B.	All	the	values	are	within	the	typical	values,	indicating	good	stereochemistry	quality	for	the	model.		The	Ramachandran	plot	in	Figure	78	shows	the	phi-psi	torsion	angles	for	all	residues	in	the	models.	Different	regions	are	coloured	according	to	more	or	less	favourable	combinations	of	
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phi-psi	 values:	 red	 areas	 correspond	 to	 the	 “core”	 regions	 of	 the	 most	 favourable	combinations.	Although	Model	A	depicts	one	 less	residue	 in	 the	 “disallowed”	regions	of	 the	plot,	Model	B	has	more	residues	in	the	most	favoured	regions	and	most	of	the	residues	with	“disallowed”	 combinations	 are	 positioned	 in	 loop	 regions	 of	 the	 model	 that	 will	 later	 be	optimised.	Because	the	percentage	of	Model	B	residues	in	the	“core”	regions	is	over	90%	and	in	Model	A	is	below	this	value,	the	former	seems	to	be	a	better	quality	model.		
		 	 	
Figure	78			Main	Ramachandran	plot	for	3ZG6	(left)	and	3K35	(right)	template	models.	Residues	with	most	favourable	 combinations	 of	 phi-psi	 are	 located	 in	 the	 red	 areas,	 accounting	 for	 87.6%	 and	 90.3%	 of	 the	 total	number	of	residues	in	each	model.		The	 graphs	 in	 Figure	 79	 and	 Figure	 80	 show	 the	 measured	 peptide	 bond	 planarity	 for	different	 planar	 groups	 in	Model	 A	 and	Model	 B.	 The	 dashed	 lines	 indicate	 the	 ideal	 value	0.03Å	 for	 aromatic	 rings	 and	 0.02Å	 for	 planar	 end-groups.	 In	 the	 case	 of	 Model	 B	 all	 the	values	 are	 below	 the	 threshold	 while	 in	 Model	 A	 some	 of	 the	 arginine	 and	 tryptophan	residues	contain	non-planar	backbone	peptide	bonds.	
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Figure	79	 	 	Histograms	showing	RMS	distances	 from	planarity	 in	Model	A	residues.	For	aromatic	residues	the	threshold	is	set	at	0.03Å,	otherwise	the	value	is	0.02Å.		
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Figure	80	 	 	Histograms	showing	RMS	distances	 from	planarity	 in	Model	B	residues.	For	aromatic	residues	the	threshold	is	set	at	0.03Å,	otherwise	the	value	is	0.02Å.		G-factors	 provide	 a	 measurement	 of	 how	 unusual	 a	 property	 is,	 with	 low	 values	corresponding	 to	 low-probability	 conformations.	 In	 PROCHECK,	 both	 torsion	 angles	 and	covalent	 geometries	 are	 computed	 (Table	 13).	 In	 the	 case	 of	 these	 models,	 most	 of	 the	parameters	 are	within	 the	 normal	 value	 range,	with	 the	 exception	 of	 the	main-chain	 bond	lengths	and	angles	in	Model	A,	and	the	main-chain	bond	angles	in	Model	B.	In	model	be	the	difference	to	the	minimum	score	(-0.5)	is	only	0.3,	resulting	in	an	overall	average	of	-0.14.	On	the	other	hand,	Model	A	contains	highly	unusual	main-chain	bond	lengths	and	angles,	which	results	in	a	considerably	lower	G-factor	score	in	comparison	to	Model	B.	This	suggests	Model	B	has	better	stereochemistry	than	Model	A.	
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Table	13			Summary	of	the	computed	G-factors	for	torsion	angles	and	covalent	geometries.	Ideally,	the	score	should	be	above	-0.5.	
	 Parameter	 Score	 Average	Score	3ZG6	 3K35	 3ZG6	 3K35	
Dihedral	angles	
Phi-psi	distribution	 -0.08	 0.03	
-0.12	 -0.02	Chi1-chi2	distribution	 -0.32	 -0.22	Chi1	only	 0.15	 0.19	Chi3	and	chi4	 0.52	 0.50	Omega	 0-40	 -0.23	
	 	 	 	Main-chain	covalent	forces	 Main-chain	bond	lengths	 -0.70	 -0.15	 -0.93	 -0.37	Main-chain	bond	angles	 -1.10	 -0.53	
	 	 	 		 Overall	average	 	 -0.42	 -0.14	
	Spatial	 structure	 analysis	 of	 the	 homology	 models	 was	 carried	 out	 with	 PROSA-web289,290.	Regarding	Model	B,	the	Z-score	of	-6.39	is	within	the	range	of	scores	typically	found	for	native	proteins	of	similar	size,	solved	with	X-ray	(Figure	81),	which	indicates	a	good	quality	model.	For	Model	A,	the	Z-score	is	significantly	lower	(-3.87),	which	positions	the	model	in	the	lower	density	area	of	typical	scores	for	X-ray	solved	proteins.		
 	
Figure	81			Z-score	plot	for	the	overall	quality	of	the	model.	
Insights	into	the	structure	of	sirtuin	7		_________________________________________________________________________________________________________________________________________________________________________	
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Moreover,	analysis	of	the	model	quality	per	residue	(Figure	82)	shows	a	general	low	energy	for	Model	B,	with	 the	 exception	of	 the	 Zn2+-binding	domain	 (residues	186-235)	 and	 the	α-helices	of	the	C-terminal	(residues	345-400).	In	Model	A,	besides	the	two	mentioned	regions,	there	 is	an	energy	 increase	corresponding	to	α2	and	α3	of	the	N-terminal	(residues	48-88),	and	α7,	β7	and	β8	of	the	Rossman-fold	domain	(residues	258-302).	I	believe	this	to	be	caused	by	the	unfavourable	position	of	the	N-terminal	connecting	loop.	
	 	
Figure	82			ProSA-web	plot	of	residue	scores	for	Model	A	(left)	and	Model	(B).	Because	a	plot	of	single	residue	energies	would	 results	 in	 large	 fluctuations	with	 limited	 information	 for	 the	model	evaluation,	 the	energies	are	averaged	over	a	40	residue	window.		Based	 on	 the	 results	 described	 here,	 template	 3K35	 produced	 a	 better	 quality	model	 than	3ZG6,	despite	 the	higher	E-value	and	slightly	different	preliminary	model	produced	(Figure	73).	As	mentioned	earlier,	 the	minor	errors	found	with	these	approaches	will	be	minimised	by	 performing	 loop	 optimisation	 and	 running	 long	 molecular	 dynamics	 simulations	 with	explicit	solvent281.		
4.4 Conclusion	Our	research	has	proposed	the	first	complete	homology	model	 for	SIRT7,	 including	both	N-	and	C-	termini.	The	catalytic	domain	was	concluded	to	be	more	similar	to	SIRT6	than	other	human	 sirtuins,	which	was	 further	 supported	 by	 the	 phylogenetic	 analysis	 that	 groups	 the	two	proteins	 in	 the	same	class	 IV.	Similarly	 to	SIRT6,	SIRT7	also	misses	 the	helix	bundle	 in	the	small	domain,	which	is	in	turn	replaced	by	a	shorter	loop.	Thus	the	result	would	be	a	loss	of	 interactions	 between	 domains	 and	 a	 differently	 shaped	 Zn2+-binding	 module.	 However,	
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SIRT7	has	an	arginine	(Arg233)	and	glutamic	acid	(Glu241)	 in	 the	same	positions	as	SIRT3	Lys288	 and	 Glu296,	 which	 indicates	 the	 conventional	 salt	 bridge	 conserved	 in	 the	 sirtuin	family	 is	 present	 in	 SIRT7	 as	 well.	 In	 the	 final	 model,	 the	 arginine	 side	 chain	 is	 oriented	towards	the	protein	surface,	enabling	formation	of	a	salt	bridge.	Further	optimisation	and	MD	simulations	will	illuminate	whether	this	is	likely	to	be	important.	Although	the	N-	and	C-termini	showed	a	well-defined	α-helix	organization,	essential	for	DNA	binding,	their	positioning	in	relation	to	the	catalytic	domain	diverged	between	Model	A	and	Model	B.	Quality	evaluation	through	PROCHECK	and	PROSA-web	showed	that	the	termini	are	more	 favourable	 when	 positioned	 closer	 to	 the	 catalytic	 core	 and	 on	 each	 side	 of	 the	structural	cleft.	Moreover,	bioinformatics	analysis	results	suggested	structure-based	function	similarities	 to	 DNA-binding	 motifs	 in	 proteins	 from	 different	 families.	 	 Furthermore,	 the	termini	are	rich	in	positively	charged	residues	like	arginine	and	lysine,	which	also	suggests	an	important	role	in	binding	to	negatively	charged	DNA.	The	 Model	 B	 showed	 an	 overall	 good	 quality	 however,	 and	 although	 these	 findings	 are	encouraging,	further	model	refinement	and	validation	need	to	be	conducted.	With	that	goal	in	mind,	 docking	 and	MD	 simulations	with	 lysine	 substrates	 and	 the	 homology	model	will	 be	performed,	as	well	as	small-angle	X-ray	scattering	(SAXS)	experiments	on	the	commercially	available	SIRT7	protein.	The	resulting	data	will	then	be	added	as	new	restraints	to	improve	the	model	quality	and	reliability.			
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5. Conclusion	and	future	perspectives		HDACs	are	 a	key	 component	of	 the	epigenetic	process	 and	different	 expression	patterns	of	members	 of	 this	 enzyme	 family	 have	 been	 found	 in	 several	 types	 of	 cancer	 and	 other	diseases.	HDACs	are	known	for	their	multitude	of	functions	and	variable	substrate	specificity,	which	 has	 encouraged	 the	 development	 of	 selective	 inhibitors,	 with	 five	 pan	 inhibitors	already	approved	for	cancer	treatment.	Molecular	 modelling	 has	 become	 an	 important	 and	 well-established	 tool	 in	 drug	 design.	Computational	methods	 can	aid	 in	 chemical	 synthesis	 through	 conformational	 analysis	 and	mechanistic	studies,	in	drug	discovery	by	using	virtual	screening,	and	in	the	rationalisation	of	enzymatic	 activity	 through	 docking	 studies	 and	 molecular	 dynamics	 simulations.	 In	 this	thesis,	 I	 report	 the	 successful	 use	 of	 molecular	 modelling	 as	 an	 integrated	 part	 of	investigating	 and	 characterising	 the	 substrate	 and	 inhibitor	 specificity	 of	 histone	deacetylases.	Docking	 studies	 and	 long	 MD	 simulations	 were	 performed	 on	 a	 series	 of	 known	 HDAC	inhibitors	 to	 evaluate	 the	HDAC:ligand	 interactions	 and	 the	 results	were	 then	 compared	 to	their	norvaline	analogues	 lacking	a	ZBG.	As	expected,	 the	hydroxamate	analogues	yield	 the	best	docking	scores,	proving	to	be	much	more	potent	inhibitors	by	mimicking	the	substrate’s	binding	 mode	 and	 competing	 for	 the	 same	 binding	 site.	 On	 the	 other	 hand,	 norvaline	analogues	projected	 the	 aromatic	 side	 chains	 towards	 the	 active	 site	 channel,	 providing	 an	explanation	 for	 the	 non-competitive	 inhibition	 result	 from	 experimental	 data.	 The	 findings	also	suggested	apicidins	to	be	the	highest	affinity	inhibitors,	while	Cyl-1	and	Cyl-2	produced	the	 best	 poses	 amongst	 the	 norvaline	 analogues.	 The	 unexpected	 interaction	 between	 the	methoxy	 group	 in	 the	 macrocycle	 side	 chain	 and	 the	 zinc	 ion	 could	 prompt	 further	investigation	 of	 a	 new	 set	 of	 HDAC	 inhibitors	 featuring	 this	 motif.	 Additional	 theoretical	studies	could	be	performed,	including	quantum-chemical	calculations	(QM/MM),	to	evaluate	the	binding	affinity	of	each	HDAC	 to	 the	different	 inhibitors	and	 the	results	 compared	with	experimental	enzymatic	activity	parameters	like	IC50.	In	 another	 part	 of	 the	 project,	 the	 sensitivity	 of	 SIRT1,	 3	 and	 5	 to	NADH	was	 investigated	through	 long	 (250ns	 and	 500ns)	 MD	 simulations.	 When	 in	 the	 AC	 conformation,	 the	nicotinamide	moiety	of	NADH	tends	to	move	away	from	the	C	pocket,	while	the	same	moiety	in	NAD+	 stays	 in	 the	productive	AC	conformation	and	establishes	hydrogen	bonds	with	 the	highly	conserved	isoleucine	and	aspartate	residues	in	the	C	pocket.	When	both	dinucleotides	
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are	 positioned	 in	 the	 AB	 pocket,	 NADH	 nicotinamide	moves	 further	 into	 the	 B	 pocket	 and	towards	the	enzyme	surface.	On	the	other	hand,	NAD+	tends	to	move	away	from	the	B	pocket	and	towards	the	productive	AC	conformation.	These	findings	provide	an	explanation	for	the	non-competitive	 inhibition	mechanism	observed	experimentally,	and	are	 in	agreement	with	the	 loss	 of	 key	 nicotinamide	 ring	 contacts	 for	 NADH.	 Furthermore,	 and	 also	 in	 agreement	with	 the	 experimental	 data,	 analysis	 of	 the	 RMSD	 values	 suggests	 a	 lower	 binding	 affinity	between	NADH	and	SIRT3	and	a	more	potent	inhibition	of	SIRT1	and	SIRT5.	In	order	to	fully	characterize	 these	 systems	 and	 evaluate	 the	 NADH	 affinity	 differences	 between	 sirtuins,	binding	energies	will	be	calculated	through	quantum-chemical	methods	(QM/MM,	MM-GBSA	and	LIE)	for	the	different	conformations.	Molecular	modelling	has	also	become	an	increasingly	important	method	to	obtain	structural	insight	 into	 protein	 structures.	 Because	 of	 the	 increasing	 number	 of	 sequenced	 proteins,	traditional	 methods	 like	 X-ray	 crystallography	 and	 NMR,	 are	 not	 able	 to	 fulfil	 the	 current	needs.	 Homology	 modelling	 allows	 the	 creation	 of	 models	 based	 on	 the	 experimental	structures	of	related	proteins	with	high	efficiency	and	low	cost.	 In	chapter	4	of	this	thesis,	 I	report	 the	 first	 complete	 homology	model	 for	 SIRT7,	 including	 both	N-	 and	 C-termini.	 The	catalytic	 domain	 of	 the	 model	 showed	 high	 similarity	 to	 other	 sirtuins,	 with	 the	 highly	conserved	residues	like	catalytic	histidine	and	zinc-binding	cysteines	modelled	correctly.	The	termini	 showed	 a	 well-defined	 α-helix	 organization,	 in	 agreement	 with	 sequence-based	secondary	 structure	 prediction	 and	 structure-based	 function	 similarity	 findings.	 This	 is	coincident	with	previous	reports	of	the	termini	 involvement	in	DNA/RNA-binding,	essential	for	the	enzyme’s	activity.	Although	these	findings	were	encouraging,	and	stereochemical	and	spatial	structure	analysis	 indicated	a	good	quality	model,	 further	refinement	and	validation	need	 to	 be	 conducted.	 In	 the	 near	 future,	 we	 will	 carry	 out	 SAXS	 experiments	 on	 the	commercial	SIRT7	in	order	to	obtain	a	rough	shape	of	the	enzyme	in	solution.	The	data	will	then	be	used	to	refine	the	model.	The	future	theoretical	studies	will	include	docking	and	MD	simulations	with	N-acyllysine	substrates	and	the	homology	model	to	investigate	the	substrate	specificity	of	this	enzyme.	Molecular	modelling	is	a	field	still	in	development	but	is	quickly	becoming	a	go-to	approach	for	efficient,	 robust	and	 less	costly	studies.	There	are	many	advantages	over	 the	 traditional	methods.	 Computer	 molecules	 are	 usually	 ease	 to	 build	 and	 to	 examine,	 especially	 if	 the	structure	 is	 large,	 and	 calculations	 can	 be	 performed	on	 unstable	molecules	 and	 transition	states.	At	the	same	time,	computational	chemistry	is	becoming	more	accessible	to	researchers	from	 other	 fields,	 with	 the	 creation	 of	 more	 user-friendly	 software.	 However,	 theoretical	
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studies	 can	 often	 produce	 different	 results	 depending	 on	 the	 chosen	 method.	 A	 close	collaboration	and	exchange	of	information	between	theoretical	and	experimental	researchers	would	bring	the	best	of	two	worlds	together	and	make	drug	discovery	more	efficient.																					
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Appendix	
Appendix	A:	Experimentals	
Chapter	2	
MacroModel	 conformational	 search:	 Ligand	 conformational	 search	was	 carried	 out	 using	the	macrocycle	conformational	sampling	algorithm291	within	MacroModel292.	This	algorithm	combines	a	modified	version	of	Labute’s	LowModeMD	(LMMD)	method293	and	MacroModel’s	large-scale	 lowmode	 (LLMOD)	 sampling294,295.	 The	 compound	 search	 used	 5000	 quench	cycles	and	up	to	5000	steps	of	LLMOD,	 followed	by	energy	minimization	of	each	conformer	found.	The	 search	was	 set	 to	 sample	 even	high	 energy	barrier	 torsional	 angles	 like	 amides	and	esters.		
Simulated	 Annealing-Molecular	 dynamics	 on	 free	 ligands:	 Trapoxin	 A/B,	 apicidin,	 and	apicidin	 A	 analogs	 were	 built	 in	 Maestro211	 using	 trapoxin	 A212	 and	 apicidin213	 X-ray	structures	as	templates,	respectively.	A	cyl-1	NMR	solution	structure214	was	used	as	template	to	build	cyl-1	and	cyl-2	analogs.	Each	analogue	was	solvated	using	10Å	diameter	TIP3P	water	boxes	 and	DMSO	 boxes,	 and	 the	 systems	were	 neutralized	 by	 adding	 one	 sodium	 ion.	 The	systems	were	then	minimized	with	the	default	relaxation	protocol	in	Desmond296	consisting	of	two	minimization	steps,	with	and	without	solute	restraints;	a	NVT	simulation	step	at	10K	with	small	time	steps	and	restraints	on	heavy	solute	atoms;	and	a	NPT	simulation	at	10K	with	restraints	on	heavy	solute	atoms297.	A	"sawtooth"	simulated	annealing	(SA)	NVT	protocol	was	used	 to	 sample	 the	 conformational	 space	 of	 each	 ligand	 in	 the	 solvent298.	 We	 gradually	increased	the	temperature	from	273K	to	565K	in	the	water	systems,	and	from	292K	to	675K	in	 the	 DMSO	 systems,	 equilibrating	 for	 2ns	 at	 each	 temperature.	 At	 the	 maximum	temperature,	 the	 systems	 were	 equilibrated	 for	 10ns	 and	 cooled	 down	 to	 273K	 (292K	 in	DMSO)	over	5ns,	with	1ns	of	 equilibration	 time.	The	 temperature	was	quickly	 increased	 to	500K	(600K	in	DMSO),	equilibrated	for	10ns,	cooled	down	to	273K	over	5ns	and	equilibrated	again	 for	 1ns.	 The	 same	 plateau	 and	 quenching	 times	 were	 applied	 to	 the	 rest	 of	 the	temperature	 increases.	 The	 last	 temperature	 drop	 was	 performed	 over	 2ns,	 with	 4ns	 of	equilibration	 time.	 The	 high	 temperatures	 used	 allow	 me	 to	 eliminate	 possible	conformational	 setup	 bias.	 After	 the	 SA	 protocol,	 the	 systems	were	 subjected	 to	molecular	dynamics	 for	 100ns	 at	 constant	 pressure.	 All	 the	 MD	 simulations	 were	 performed	 with	periodic	boundary	conditions	with	the	Nose–Hoover	chain	thermostat299,300	set	to	300K	and	a	relaxation	time	of	1ps.	The	Martyna–Tobias–Klein	barostat301	was	used	to	regulate	pressure	to	 1bar	 with	 isotropic	 coupling	 and	 a	 relaxation	 time	 of	 2ps.	 Equations	 of	 motion	 were	
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integrated	using	the	RESPA	integrator302	with	bonded,	near	and	far,	time	steps	of	2,	2	and	6	femtoseconds,	respectively.	Non-bonded	interactions	were	subjected	to	a	cutoff	of	9Å.	Long-range	 electrostatics	 were	 treated	 with	 the	 smooth-particle	 mesh	 Ewald	 method303	 with	 a	tolerance	of	10−9	and	the	OPLS3	force	field232,233,304	was	used	to	describe	the	systems.		
HDAC	structure	preparation:	The	crystal	structures	of	HDAC2	(PDBID:	4LY1)305	and	HDAC3	(PDBID:	 4A69)306	 were	 used	 to	 dock	 the	 previously	 mentioned	 ligands.	 HDAC2	 crystal	structure	 contains	 three	 identical	monomers	 consisting	 of	 the	 histone	 deacetylase	 domain,	and	 4-(acetylamino)-N-[2-	 amino-5-(thiophen-2-yl)phenyl]benzamide.	 HDAC3	 contains	 two	identical	monomers	 consisting	 of	 the	 histone	 deacetylase	 domain	 (chain	A	 and	B),	 and	 the	nuclear	receptor	corepressor	2	and	inositol	tetraphosphate	(chain	C	and	D).	Despite	the	high	similarity	between	 the	deacetylase	domain	of	 each	monomer,	 the	position	of	 several	water	molecules	differs.	Because	these	subtle	differences	could	influence	the	docking,	 I	decided	to	eliminate	all	water	molecules	and	re-solvate	the	systems	after	docking	and	previous	to	MD.	Each	complex	was	individually	prepared	with	the	Protein	Preparation	Wizard.	Missing	atoms	were	added	and	protonation	states	at	pH	7.4	were	assigned	with	PROPKA307.		
Docking	and	molecular	dynamics	simulations	on	HDAC:ligand	complexes:	After	docking,	the	 complexes	 were	 neutralized,	 by	 adding	 extra	 sodium	 and	 chloride	 ions,	 and	 solvated	using	 10	 Å	 diameter	 TIP3P	water	 boxes.	 They	were	 then	minimized	with	 the	 default	 pre-simulation	 protocol	 in	 Desmond	 consisting	 of	 two	 minimization	 steps,	 with	 and	 without	solute	restraints;	a	NVT	simulation	step	at	10	K	with	small	time	steps	and	restraints	on	heavy	solute	 atoms;	 a	 NPT	 simulation	 at	 10	 K	 with	 restraints	 on	 heavy	 solute	 atoms;	 and	 a	unrestrained	 NPT	 simulation	 step.	 Each	 simulation	 was	 carried	 out	 for	 250	 ns	 and	 the	coordinates	 and	 energies	 were	 saved	 at	 10	 ps	 intervals.	 Figures	 were	 generated	 with	Pymol308.	
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Chapter	3	
Molecular	 dynamics	 simulations	 on	 Sirtuin:peptide:NAD+/NADH	 complexes:	 Molecular	dynamics	 studies	 of	 NAD	 binding	 sites	 and	 docking	 of	 NADand	 NADH	 were	 conducted	 in	Desmond296.	The	crystal	structure	coordinates	 for	SIRT1/EX527/NAD+	(PDBID:	4I5I)309	and	SIRT3/FZN/ADPR	 (PDBID:	 3GLT)237	 were	 used	 to	 construct	 the	 models	 for	 molecular	dynamics	simulations.	SIRT1	ternary	complexes	were	built	by	replacing	the	inhibitor	EX527	with	the	substrate	AceCS2	(from	3GLR)	and	modifying	NAD	to	NADH.	SIRT3	complexes	were	obtained	by	replacing	the	ADPR	ligand	with	NAD(from	3RIY)	or	NADH	(modified	from	NAD)	and	 the	 FZN	 ligand	 with	 an	 AceCS2	 peptide	 (from	 3GLR),	 giving	 systems	 with	 the	dinucleotide	bound	in	the	AC	site	or	modified	to	accommodate	the	dinucleotide	bound	in	the	alternative	AB	site.	Each	system	was	neutralized	by	adding	sodium	ions	and	solvated	with	a	cubic	 TIP3P	water	 box	 having	 at	 least	 12Å	 thickness.	 Additional	 sodium	 and	 chloride	 ions	were	 introduced	 to	 achieve	 a	 salt	 concentration	 of	 0.15M	 (physiological	 conditions).	 The	resulting	 systems	 (51,000–77,000	 atoms)	 were	 then	 treated	 using	 either	 the	 default	presimulation	protocol	in	Desmond2	(SIRT1)	or	a	modified	presimulation	protocol	where	the	relaxation	time	was	extended	from	1ps	to	1ns	with	gradual	increase	of	the	temperature	from	100K	 to	 300K.	 A	 production	 run	was	 then	 carried	 out	 for	 either	 250ns	 (AC	 structures)	 or	500ns	 (AB	structures)	at	300K	using	OPLS3	 force	 field304.	We	 found	 that	OPLS3	performed	better	than	OPLS2005	in	replicating	pyramidalization	of	the	pyridyl	nitrogen	of	NADH	found	using	DFT	 (density	 functional	 theory)	 calculations310,311.	 Periodic	boundary	 conditions	with	the	Nose-Hoover	chain	thermostat299,300	and	the	Martyna-Tobias-Klein	barostat301	were	used,	with	sampling	of	coordinates	and	energies	at	10ps	intervals.	Two	replicates	were	performed	for	each	system.	Figures	were	generated	with	Pymol308.	
																																								 																					2 	The	 protocol	 consists	 of	 two	 minimization	 steps,	 with	 and	 without	 solute	 restraints;	 a	 NVT	simulation	step	at	10K	with	small	time	steps	and	restraints	on	heavy	solute	atoms;	a	NPT	simulation	at	10K	with	restraints	on	heavy	solute	atoms;	and	a	unrestrained	NPT	simulation	step.	
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Chapter	4	
Sequence	alignments:	To	determine	the	conserved	nucleotide	regions	found	in	other	human	sirtuins	 and	 inferred	 for	 SIRT7	 from	 sequence	 similarity,	 I	 aligned	 the	 protein	 sequences	obtained	 from	 Uniprot	 (www.uniprot.org)272	 (SIRT1,	 Q96EB6;	 SIRT2,	 Q8IXJ6;	 SIRT3,	Q9NTG7;	 SIRT4,	 Q9Y6E7;	 SIRT5,	 Q9NXA8;	 SIRT6,	 Q8N6T7;	 Sirt7,	 Q9NRC8)	 using	 the	NCBI	tool	COBALT312.		
Phylogenetic	tree	and	SDP	score:	X-ray	structures	of	SIRT1,	2,	3,	5	and	6	(PDBID:	4KXQ313,	5D7O314,	 4JSR315,	 3RIY117	 and	3ZG6254,	 respectively),	 and	bacterial	 sirtuins	 (PDBID:	1S5P316,	1Q17317,	 4IAO,318	 1ICI319,	 1S7G114,	 3U31320,	 2H59238	 and	 5A3A321)	 were	 used	 for	 structural	alignment	with	MUSTANG322.	All	chordate	sequences	of	SIRT1-7	available	from	Uniprot	were	downloaded	 and	 added	 using	 ClustalO323.	 The	 structure-based	 alignment	 was	 manually	edited	 with	 Jalview279.	 Structure-aware	 phylogenetic	 tree	 was	 created	 using	 ClustalO	 and	edited	 using	 Dendroscope324,325.	 To	 identify	 sites	 within	 SIRT7	 subjected	 to	 evolutionary	pressure,	the	previous	sample	of	sirtuin	sequences	was	subsampled	to	a	set	of	93,	including	all	 human	 sirtuins,	 and	 each	 sequence	was	 assigned	 a	 class	 (I,	 II,	 III	 or	 IV).	 The	 GroupSim	algorithm326	was	then	applied	to	the	alignment.	
Structural	 analysis:	 Homology	 modelling	 study	 was	 conducted	 using	 the	 MODELLER	protocol327	and	crystal	structures	of	human	and	bacterial	sirtuins	mentined	above.	All	crystal	structures	were	download	from	the	Protein	Data	Bank	(www.rcsb.org)328.	
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Supp.	Figure	1			Secondary	structure	prediction	of	human	SIRT1,	2	and	3.	Blue	areas	represent	α-helices	and	green	areas	are	β-strands.	The	position	of	 the	conserved	are	highligted	as:	catalytic	histidine	 in	purple	and	zinc	binding	cysteines	in	orange.		
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Supp.	Figure	1	(continuation)			Secondary	structure	prediction	of	human	SIRT4	and	5.					
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Supp.	Figure	2			Structure-based	sequence	alignment	of	the	catalytic	core	of	SIRT7	higher	eukaryote	homologues.	Due	to	the	 length	of	the	alignment,	31	sequences	out	of	the	110	are	displayed.	The	colouring	indicates	conservation	based	on	the	BLOSUM62	score.		
		________________________________________________________________________________________________________________________________________________________________________	
	 154	
	
Supp.	Figure	3			Alignment	between	SIRT7	target	sequence	and	SIRT1	template	sequence	from	PsiBlast	(A)	and	
HHsearch(B)	 ,	 in	 fasta	 format.	 The	 position	 of	 the	 conserved	 are	 highligted	 as:	 catalytic	 histidine	 in	 purple,	 zinc	binding	cysteines	in	orange	and	NAD+	binding	region	in	grey.	
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Supp.	Figure	4			Alignment	between	SIRT7	target	sequence	and	SIRT2	template	sequence	from	Blast	(A)	PsiBlast	
(B)	and	HHsearch(C)	,	in	fasta	format.	Colour	scheme	as	in	Supp.	Figure	3.	
A	
B	
C	
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Supp.	Figure	5			Alignment	between	SIRT7	target	sequence	and	SIRT3	template	sequence	from	Blast	(A)	PsiBlast	
(B)	and	HHsearch(C)	,	in	fasta	format.	Colour	scheme	as	inSupp.	Figure	3.	
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Supp.	Figure	6			Alignment	between	SIRT7	target	sequence	and	SIRT5	template	sequence	from	PsiBlast	(A)	and	
HHsearch(B)	,	in	fasta	format.	Colour	scheme	as	in	Supp.	Figure	3.	
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Supp.	Figure	7			Alignment	between	SIRT7	target	sequence	and	SIRT6	template	sequence	from	Blast	(A)	PsiBlast	
(B)	and	HHsearch(C)	,	in	fasta	format.	Colour	scheme	as	in	Supp.	Figure	3.	
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Supp.	Figure	8	 	 	Alignment	between	SIRT7	target	sequence	and	Sir2	template	sequence	from	PsiBlast,	 in	
fasta	format.	Colour	scheme	as	in	Supp.	Figure	3.	
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Supp.	Figure	9			Alignment	between	SIRT7	target	sequence	and	Sir2	template	sequence	from	HHsearch,	in	
fasta	format.	Colour	scheme	as	in	Supp.	Figure	3.	
	
	
Supp.	Table	1			RSMD	values	(Å)	for	the	models	built	with	the	previous	alignments	from	human	sirtuins.	
	 Blast	 PsiBlast	
	 PDBID	 SIRT2	 SIRT3	 SIRT6	 SIRT1	 SIRT2	 SIRT3	 SIRT5	 SIRT6	
PsiBlast	
SIRT1	 	 	 	 	 	 	 	 	
SIRT2	 3.036	 	 	 	 	 	 	 	
SIRT3	 	 4.602	 	 	 	 	 	 	
SIRT5	 	 	 	 	 	 	 	 	
SIRT6	 	 	 0.923	 	 	 	 	 	
HHsearch	
SIRT1	 	 	 	 1.955	 	 	 	 	
SIRT2	 3.615	 	 	 	 1.315	 	 	 	
SIRT3	 	 3.935	 	 	 	 0.957	 	 	
SIRT5	 	 	 	 	 	 	 1.092	 	
SIRT6	 	 	 1.087	 	 	 	 	 0.479	
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Supp.	Table	2	 	 	 RSMD	values	 (Å)	 for	 the	models	 built	with	 the	previous	PsiBlast	 alignments	 from	yeast	
sirtuins.	
PDBID	 1ICI	 1Q17	 1S5P	 1S7G	 2H59	 3U31	
1ICI	 0	 	 	 	 	 	
1Q17	 4.268	 0	 	 	 	 	
1S5P	 2.139	 4.836	 0	 	 	 	
1S7G	 3.167	 3.592	 3.893	 0	 	 	
2H59	 2.289	 2.834	 3.331	 2.778	 0	 	
3U31	 2.334	 3.988	 3.209	 3.648	 3.252	 0	
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ABSTRACT: Histone deacetylases (HDACs) are validated targets
for treatment of certain cancer types and play numerous regulatory
roles in biology, ranging from epigenetics to metabolism. Small
molecules are highly important as tool compounds for probing these
mechanisms as well as for the development of new medicines.
Therefore, detailed mechanistic information and precise character-
ization of the chemical probes used to investigate the eﬀects of
HDAC enzymes are vital. We interrogated Nature’s arsenal of
macrocyclic nonribosomal peptide HDAC inhibitors by chemical
synthesis and evaluation of more than 30 natural products and
analogues. This furnished surprising trends in binding aﬃnities for
the various macrocycles, which were then exploited for the design of
highly potent class I and IIb HDAC inhibitors. Furthermore, thorough kinetic investigation revealed unexpected inhibitory
mechanisms of important tool compounds as well as the approved drug Istodax (romidepsin). This work provides novel
inhibitors with varying potencies, selectivity proﬁles, and mechanisms of inhibition and, importantly, aﬀords insight into known
tool compounds that will improve the interpretation of their eﬀects in biology and medicine.
Histone deacetylase (HDAC) enzymes are importantregulators of posttranslational modiﬁcations (PTMs) on
lysine residues in the proteome.1,2 Humans have 18 diﬀerent
isoforms of these enzymes, zinc-dependent HDAC1−113 and
NAD+-dependent sirtuins 1−7 (SIRT1−7), respectively,4
which are classiﬁed according to sequence similarity and
localize to diﬀerent cellular compartments.5,6 Given their
importance in epigenetic regulation through the maintenance
of histone protein acetylation levels in chromatin, nuclear class
I HDAC1−3 in particular, are targets for cancer chemo-
therapeutics that are clinically used.7 However, HDAC
isoforms, including those with diﬀerent subcellular localization,
have been implicated in a wide variety of conditions and
biological functions, such as immune disease,8 neurodegener-
ative diseases,8,9 cognition,10,11 vision,12 metabolism,13 and
HIV.14,15 Some enzymes have even been shown to target PTMs
other than ε-N-acetyllysine (Kac) in the regulation of protein
activity.16−19 Because of the complexity of these highly dynamic
networks of posttranslational protein modiﬁcation, chemical
tool compounds with high speciﬁcity and potency against
HDACs are desired to oﬀer alternatives to genetic manipulation
in the interrogation of HDAC-mediated regulation in healthy
and diseased cells.
Naturally occurring nonribosomal cyclopeptides oﬀer a rich
source of inspiration for the design of HDAC inhibitors (Figure
1a−c),20 with bicyclic depsipeptide romidepsin (1, also known
as FK-228 or Istodax) being one of the handful of HDAC
inhibitors currently approved for treatment of certain cancers.7
Mimicking the binding of substrates to HDAC enzymes
(Figure 1d) by interacting with both the catalytic site Zn2+
atom and the surface where protein−protein interaction
between HDAC and substrate protein takes place (Figure
1e), these natural products generally exhibit potent class I
HDAC inhibition in the nanomolar range.20 It is well
established that cyclization is important for potency,21 and
examples of macrocycles without zinc-binding groups have
been shown to inhibit HDACs, albeit not surprisingly at
potencies lower than those of their zinc-binding parent
compounds.22,23 Through evolution, however, Nature has
endowed this class of inhibitors with a variety of diﬀerent
zinc-binding groups, which complicates elucidation of the
importance of diﬀerent macrocycles on binding aﬃnity and
isozyme selectivity. Chemical synthesis of structurally edited
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natural product analogues can help answer this question to
provide insight for the design of novel high-aﬃnity inhibitors
(Figure 1f).
Here, we ﬁrst synthesized a series of natural product-derived
macrocycles and determined their potencies and degrees of
selectivity toward recombinant zinc-dependent HDAC iso-
forms. A selection of scaﬀolds was then decorated with various
zinc-binding groups or masked zinc-binding groups in the form
of esters and thoroughly evaluated for HDAC inhibitory
potency, mode of inhibition through enzyme kinetic experi-
ments, and eﬃcacy in cell-based assays. Our results reveal
surprising diﬀerences in the potencies of naturally occurring
macrocycles against recombinant HDAC enzymes in vitro. This
insight enabled the design of highly potent inhibitors, revealed
by kinetic evaluation to exhibit a slow, tight-binding mechanism
of inhibition at picomolar Ki values.
■ EXPERIMENTAL PROCEDURES
Biochemical Materials. HDAC1 [purity of ≥62 or ≥69%
as determined by sodium dodecyl sulfate−polyacrylamide gel
electrophoresis (SDS−PAGE) according to the supplier],
HDAC2 (full length, purity of ≥94, ≥88, or ≥86% as
determined by SDS−PAGE according to the supplier), the
HDAC3−NCoR2 complex (purity of ≥90 or ≥80% as
determined by SDS−PAGE according to the supplier),
HDAC4 (purity of ≥89% as determined by SDS−PAGE
according to the supplier), HDAC5 (purity of ≥90% as
determined by SDS−PAGE according to the supplier),
HDAC6 (purity of ≥88% as determined by SDS−PAGE
according to the supplier), HDAC8 (purity of ≥90% as
determined by SDS−PAGE according to the supplier),
HDAC9 (purity of ≥76% as determined by SDS−PAGE
according to the supplier), and HDAC10 (purity of ≥21 or
≥28% as determined by SDS−PAGE according to the supplier)
were purchased from BPS Bioscience (San Diego, CA).
HDAC7 (purity of ≥90% as determined by SDS−PAGE
according to the supplier) was purchased from Millipore EMD
(Temecula, CA). HDAC6 (purity of ≥90% as determined by
SDS−PAGE according to the supplier) and HDAC11 (purity
of ≥50% as determined by SDS−PAGE according to the
supplier) were purchased from Enzo Life Sciences (Postfach,
Switzerland). Fluorescence-based assays were performed in
“Bradner/Mazischek” assay buﬀer {HEPES/Na (50 mM), KCl
(100 mM), Tween 20 [0.001% (v/v)], tris(2-carboxyethyl)-
phosphine (TCEP, 200 μM) (pH 7.4), and bovine serum
albumin (BSA, 0.5 mg/mL)}24 unless otherwise stated.
Alternatively, ﬂuorescence-based assays were performed in
Tris buﬀer [Tris-HCl (50 mM), NaCl (137 mM), KCl (2.7
mM), MgCl2 (1 mM, pH 8.0), and BSA (0.5 mg/mL)].
Romidepsin (catalog no. SML1175), trapoxin A (catalog no.
Figure 1. Macrocyclic HDAC inhibitors. (a) Thiol-containing prodrugs, romidepsin (1) and largazole (2), both revealing free thiols intracellularly
(scissile bond colored red). (b) Epoxy ketone-containing macrocycles. (c) Macrocyclic HDAC inhibitors containing other zinc-binding groups. (d)
Example of substrate binding, hHDAC8:Kac-substrate co-crystal complex [Protein Data Bank (PDB) entry 5DC8]. (e) Example of macrocyclic
HDAC inhibitor binding, zHDAC6:HC-toxin co-crystal complex (PDB entry 5EFJ). (f) HDAC inhibitor pharmacophore (the surface-binding
group, linker, and zinc-binding group are colored blue, gray, and orange, respectively).
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T2580), HC-toxin (catalog no. H7270), apicidin (catalog no.
A8851), trichostatin A (catalog no. T8552), trypsin (catalog no.
T1426, TPCK-treated from bovine pancreas), and BSA
(catalog no. A7030, heat shock fraction, protease and fatty
acid free, essentially globulin free) were from Sigma-Aldrich
(Steinheim, Germany). For assaying, synthesized peptides were
reconstituted in dimethyl sulfoxide (DMSO), and accurate
concentrations were determined by ultraviolet (UV) or
analytical high-performance liquid chromatography containing
internal standards. Human cell lines Jurkat (88042803), HL-60
(98070106), MCF-7 (86012803), and HeLa (93021013) were
purchased from Sigma-Aldrich. The MTT cell growth kit
(CT02) was purchased from Millipore EMD. The antibodies
anti-Ac-histone H3 (AH3-120, sc-56616), anti-Ac-histone H4
(E-5, sc-377520), goat anti-mouse IgG-HRP (sc-2005), anti-β-
actin (1, sc-130300), and anti-α-tubulin (6-11B-1, sc-23950)
were purchased from Santa Cruz Biotechnology (Dallas, TX).
NuPAGE Novex 4−12% Bis-TriGel, NuPAGE Novex sample
reducing agent (10×), NuPAGE Novex LDS sample buﬀer
(4×), NuPAGE Novex MES SDS running buﬀer (20×), and
NuPAGE Novex transfer buﬀer (20×) were purchased from
Life Technologies (Nærum, Denmark). SimplyBlue Safe Stain
(Coomassie stain) was purchased from Invitrogen (Carlsbad,
CA). TBS buﬀer [Tris-HCl (10 mM), NaCl (150 mM), and
Tween 20 (0.05%) (pH 7.5)] was from G-Biosciences (St.
Louis, MO). The polyvinylidene diﬂuoride (PVDF) transfer
membrane was from Amersham Pharmacia Biotech (Buck-
inghamshire, United Kingdom). The ECL Prime Western
Blotting System solution (GERPN2232, solutions A and B)
and the Ponceau S powder (P3504) were purchased from
Sigma-Aldrich (Steinheim, Germany).
Fluorescence-Based HDAC Inhibition Assays. All
reactions were performed in black low-binding Corning half-
area 96-well microtiter plates with duplicate series in each assay,
and each assay was performed at least twice. After the addition
of the relevant substrate, inhibitor, and trypsin (for continuous
measurement assays) to each well, the experiment was initiated
by addition of a freshly prepared solution of HDAC. Control
wells without enzyme were included in each plate. All reactions
were performed in assay buﬀer, with appropriate concentrations
of substrates and inhibitors obtained by dilution from 0.5−50
mM stock solutions in DMSO and an appropriate concen-
tration of enzyme obtained by dilution of the stock provided by
the supplier. The DMSO concentration in the ﬁnal assay
solution did not exceed 1% (v/v). All plates were analyzed
using a PerkinElmer Life Sciences EnSpire plate reader with
excitation at 360 nm and detection of emission at 460 nm.
Fluorescence measurements (relative ﬂuorescence units) were
converted to AMC concentrations based on an [AMC]−
ﬂuorescence standard curve, and background ﬂuorescence was
subtracted. All data were analyzed by nonlinear regression using
GraphPad Prism.
Recombinant HDAC End-Point Inhibition Assays.
Protocols were adapted from the work of Bradner, Mazitschek,
and co-workers.24 The HDAC enzyme was incubated with the
relevant substrate and inhibitor in assay buﬀer in a total volume
of 25 μL using the following ﬁnal concentrations: HDAC1
(2.5−9 ng/μL), HDAC2 (0.7−1.5 ng/μL), HDAC3 (0.2−1.2
ng/μL), HDAC4 (0.04 ng/μL), HDAC5 (0.05−0.2 ng/μL),
HDAC6 (2.4−2.7 ng/μL), HDAC7 (4 ng/μL), HDAC8 (0.1−
2.5 ng/μL), HDAC9 (0.4−0.8 ng/μL), HDAC10 (10−41 ng/
μL), and HDAC11 (10−50 ng/μL) and Ac-Leu-Gly-Lys(Ac)-
AMC (20 μM for HDAC1−3, -6, and -11), Ac-Leu-Gly-
Lys(Tfa)-AMC (20 μM for HDAC4, 120 μM for HDAC5, 40
μM for HDAC7, 200 μM for HDAC8, and 80 μM for
HDAC9), and Ac-Arg-His-Lys(Ac)-Lys(Ac)-AMC (5 μM for
HDAC10). The plate was incubated at 37 °C for 30 min, then a
solution of trypsin (25 μL, 0.4 mg/mL) added, and assay
development allowed to proceed for 15 min at room
temperature, before ﬂuorescence analysis. Fractional residual
activity (νi/ν0) was calculated, and assuming a standard fast-on/
fast-oﬀ mechanism, Ki values were obtained by ﬁtting the
resulting data to eq 1 shown below, by applying previously
reported Km values for HDAC1−3, HDAC6, and HDAC8,24
HDAC10,25 and HDAC11.26
Recombinant HDAC Rate Inhibition Assays, Dose
Response. Hydrolase activities of HDACs were evaluated at
varying inhibitor concentrations (2-fold dilutions). The HDAC
enzyme was incubated with the relevant substrate and inhibitor
and trypsin in assay buﬀer in a total volume of 50 μL using the
following ﬁnal concentrations: HDAC1 (200 pg/μL), HDAC2
(100 pg/μL), HDAC3 (100 pg/μL), HDAC6 (400 pg/μL),
HDAC8 (400 pg/μL), Ac-Leu-Gly-Lys(Ac)-AMC (20 μM for
HDAC1−3 and -6), Arg-His-Lys(Ac)-Lys(Ac)-AMC (400 μM
for HDAC8), and trypsin (5 ng/μL for HDAC1−3 and -8 and
4 ng/μL for HDAC6). Hydrolase activities in Tris buﬀer at
varying inhibitor concentrations (2-fold dilutions) were
determined in the same manner, using HDAC1 (200 pg/μL),
Ac-Leu-Gly-Lys(Ac)-AMC (20 μM), and trypsin (5 ng/μL). In
situ ﬂuorophore release was monitored immediately by
ﬂuorescence readings recorded every 30 s for 60 min at 25
°C. The data were ﬁtted to the relevant equations [eq 2 or 3
(see below)] to obtain either initial linear rates (ν) or the
apparent ﬁrst-order rate constant (kobs) for each inhibitor
concentration. Secondary plots were then ﬁtted to the relevant
equations [eq 1, 4, or 5 (see below)] to obtain the desired
dissociation constants (Ki and Ki,1) and/or kinetic parameters
(k1, k−1, k2, and k−2).
Recombinant HDAC Rate Inhibition Assays with One
Inhibitor. Hydrolase activities of HDAC1−3 were evaluated at
varying substrate and inhibitor concentrations (2-fold dilu-
tions). The HDAC enzyme was incubated with the substrate,
the relevant inhibitor, and trypsin in assay buﬀer in a total
volume of 50 μL using the following ﬁnal concentrations:
HDAC1 (200 pg/μL), HDAC2 (100 pg/μL), HDAC3 (200
pg/μL), Ac-Leu-Gly-Lys(Ac)-AMC (100−3.13 μM), and
trypsin (5 ng/μL for HDAC1 and -2 and 3 ng/μL for
HDAC3). In situ ﬂuorophore release was monitored immedi-
ately by ﬂuorescence readings recorded every 30 s for 60 min at
25 °C. The initial linear rates (ν) obtained were ﬁtted globally
to the relevant equations for competitive and noncompetitive
inhibition [eqs 6 and 7, respectively (see below)] to obtain
competitive and uncompetitive inhibition constants (Kis and Kii,
respectively) and Michaelis−Menten parameters (Vmax and KM)
and construct replots of the obtained relative Vmax and Vmax/KM
[eqs 8 and 9, respectively (see below)].
Recombinant HDAC Rate Inhibition Assays with Two
Inhibitors. Hydrolase activity of HDAC3 was evaluated at
varying concentrations of inhibitors 4a (TpxBNva) and 4e
(TpxBAoda) (2- and 4-fold dilutions, respectively). The HDAC
enzyme was incubated with the substrate, inhibitors, and
trypsin in assay buﬀer in a total volume of 50 μL using the
following ﬁnal concentrations: HDAC3 (200 pg/μL), Ac-Leu-
Gly-Lys(Ac)-AMC (20 mM), and trypsin (3 ng/μL). In situ
ﬂuorophore release was monitored immediately by ﬂuorescence
readings recorded every 30 s for 60 min at 25 °C. The initial
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linear relative rates (νi/ν0) obtained were ﬁtted globally to the
relevant equation [eq 11 (see below)] to obtain apparent
dissociation constants (IC50,A and IC50,B) and the apparent
interaction term (βAB).
Data Fitting. Dose Response. Assuming fast on and oﬀ
rates for the enzyme−inhibitor equilibrium, and assuming that
equilibrium was therefore obtained before the onset of the
experiment, dose−response curves can be generated on the
basis of end-point assays.
The enzyme−inhibitor dissociation constant (Ki) can be
obtained by ﬁtting the relative conversion (νi/ν0) as a function
of log[I] to
ν
ν = − + −
+
⎡
⎣⎢
⎤
⎦⎥( ) K h
1
log[I] log 1 log
K
i
0 [S]
i
1 10 M (1)
where νi and ν0 are the observed rates with and without
inhibitor, respectively, [S] and [I] are the substrate and
inhibitor concentrations, respectively, KM is the Michaelis−
Menten constant, and h is the Hill coeﬃcient.
Kinetic Analysis of Rate Inhibition Assays. Similarly, if the
inhibition equilibrium indeed follows a fast-on/fast-oﬀ
mechanism, linear progress curves are observed when
monitoring product formation ([P]) as a function of time
ν= t[P] (2)
and the enzyme−inhibitor dissociation constant (Ki) can be
determined by ﬁtting a secondary plot of the relative rates (νi/
ν0) as a function of log[I] to eq 1.
However, if the enzyme−inhibitor equilibrium is reached
slowly and therefore not achieved prior to the onset of the
experiment, nonlinear progress curves will be obtained. Slow,
competitive binding of an inhibitor may be divided into two
mechanisms. In mechanism A, the enzyme−inhibitor complex
forms without kinetically observable intermediates, whereas in
mechanism B, an equilibrium is rapidly established with an
initial complex, which is then converted to a second stable
complex displaying rate-determining kinetics. For both types of
slow binding kinetics, product formation as a function of time
follows eq 3.
ν ν ν= + − − −t
k
[P] (1 e )k tss
in ss
obs
obs
(3)
Initial and ﬁnal steady-state velocities (νin and νss, respectively)
and the apparent ﬁrst-order rate constant for establishment of
the enzyme−inhibitor equilibrium (kobs) can then be
determined. The fast-on/fast-oﬀ mechanism discussed above
is the limiting case of mechanism A when kobs is very large ([P]
= νsst). Secondary plots of kobs as a function of inhibitor
concentration (kobs vs [I]) allow determination of the binding
mechanism. For mechanism A, the relationship between kobs
and [I] is linear
= + + −
⎛
⎝⎜
⎞
⎠⎟k k K k1
[S] [I]obs 1
M
1
(4)
whereas the same relationship is hyperbolic for mechanism B.
=
+ +
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k
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K
k
[I] 1
[I]
K
obs
2
i,1
[S] 2
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This also allows calculation of the rate and dissociation
constants involved (k1, k−1, and Ki for mechanism A and Ki,1, k2,
k−2, and Ki for mechanism B).
Steady-State Analysis of the Inhibition Mechanism. For
inhibitors that employ the fast-on/fast-oﬀ mechanism, the
kinetic inhibition mechanism can be determined by global
ﬁtting of a secondary plot of series of rates (νi) as functions of
substrate concentration obtained at ﬁxed inhibitor concen-
trations, to obtain Michaelis−Menten parameters (Vmax and
KM), and the competitive and uncompetitive dissociation
constants (Kis and Kii, respectively). The investigated inhibitors
exhibit a competitive or noncompetitive inhibition mechanism.
For competitive inhibitors, the rates can be ﬁtted to
ν =
+ +( )
V
K
[S]
1 [S]
K
i
max
M
[I]
is (6)
and for noncompetitive inhibitors, the rates can be ﬁtted to
ν =
+ + +( ) ( )
V
K
[S]
1 [S] 1
K K
i
max
M
I I
is ii (7)
Evaluation of the ﬁt for the two models was performed by
replotting the obtained values to
ν
ν = +
1
1
K
max,i
max,0
[I]
ii (8)
and
ν
ν = +
K
K
( / )
( / )
1
1
K
max M i
max M 0
[I]
is (9)
For competitive inhibitors, where Kii is inﬁnite, eq 8 simpliﬁes
to νmax,i/νmax,0 = 1, corresponding to an unchanged νmax in the
investigated inhibitor range.
Mutual Exclusivity Studies. For two inhibitors (IA and IB)
both employing the fast-on/fast-oﬀ mechanism, the inﬂuence of
the binding of either inhibitor on binding of the other inhibitor
to the enzyme target may be investigated (Figure 4a).27 By
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global ﬁtting of a secondary plot of series of relative rates (νAB/
ν0) as functions of the concentration of one inhibitor ([IA] or
[IB]) obtained at ﬁxed concentrations of the other inhibitor
([IB] or [IA]), an interaction term, αAB, may be determined. If
inhibitors IA and IB are completely mutually exclusive (i.e., EIAIB
is not formed), the interaction term is inﬁnite. If inhibitors IA
and IB bind independently to the enzyme, αAB equals 1; on the
other hand, 1 ≪ αAB < ∞ indicates some degree of
nonexclusivity (i.e., EIAIB is formed, but binding of one
inhibitor decreases the aﬃnity of the other) and 1 > αAB > 0
indicates a synergistic binding of the inhibitors. For one
competitive and one noncompetitive inhibitor (as in the case of
inhibitors 4e and 4a, respectively), the relative rates can be
ﬁtted to
ν
ν =
+ + +
α+ +
α
+
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which simpliﬁes to
ν
ν = + + + β
1
1
i
0
[I ]
IC
[I ]
IC
[I ][I ]
IC IC
A
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B
50,B
A B
AB 50,A 50,B (11)
when substrate concentration is kept constant and when
Figure 2. Side chain-modiﬁed macrocyclic inhibitors. (a) Structures of macrocycles with the zinc-binding groups excised. (b) Inhibition of HDAC1−
11 at an inhibitor concentration of 10 μM (gray squares indicate no testing) (see Supporting Figure 4 for additional details). (c) Inhibition constants
(Ki values) against HDAC1−3 (see Supporting Figure 5 for additional details). (d) Structures of macrocycles with reintroduced zinc-binding groups
and dose−response curves against HDAC3 (additional data and proﬁling are available in Supporting Table 1 and Supporting Figures 11 and 12).
*Recombinant HDAC3 is in complex with a deacetylase activating domain (DAD) of NCoR2 (nuclear co-repressor 2). IA indicates “inactive”
compounds, exhibiting <50% inhibition at an inhibitor concentration of 100 μM. Abbreviations: Pip, pipicolic acid; Hex, hexyl; Aib, 2-
aminoisobutyric acid; Hha, (R)-3-hydroxyheptanoic acid; Nva, norvaline; Nle, norleucine; Aoa, (S)-2-aminooctanoic acid; Amha, (2S,3R)-3-amino-
2-methylhexanoic acid; Aoda, (S)-2-amino-8-oxodecanoic acid; Asu, (S)-2-aminosuberic acid; Asu(Et), (S)-2-amino-8-(ethoxy)-8-oxooctanoic acid;
Asu(Oct), (S)-2-amino-8-(octyloxy)-8-oxooctanoic acid; Asuha, (S)-2-amino-8-(hydroxyamino)-8-oxooctanoic acid.
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In the latter case, rather than determining the interaction term
(αAB) directly, we determine an apparent interaction term (βAB,
which is proportional to αAB). For mutually exclusive inhibitors,
both terms are inﬁnite. Also, Yonetani−Theorell plots showing
reciprocal relative rates (ν0/νAB) as a function of either
inhibitor give parallel lines for mutually exclusive inhibitors.28
Growth Inhibition Assays. Cell viability was assessed
using the MTT cell growth kit. Cells were cultivated in ﬂat 96-
well tissue culture plates. HeLa and MCF-7 cells were
cultivated in Minimum Essential Eagle’s Medium supplemented
with a 2 mM L-glutamine solution, a 1% nonessential amino
acid solution, 10% fetal bovine serum (FBS), and 1% penicillin/
streptomycin; HEK293 cells were cultivated in Dulbecco’s
Modiﬁed Eagle’s Medium supplemented with 10% FBS and 1%
penicillin/streptomycin, and HL60 and Jurkat cells were
cultivated in RPMI-1640 medium supplemented with 10%
FBS and 1% penicillin/streptomycin. HeLa and HEK293 cells
were seeded at a density of 5000 cells/well, and MCF-7, HL60,
and Jurkat cells were seeded at a density of 10000 cells/well in
90 μL of culture medium. After cultivation overnight at 37 °C
in a humid 5% CO2 atmosphere, 10 μL of culture medium
containing appropriate concentrations of inhibitor or controls
(DMSO and romidepsin) was added. The dilution series were
prepared from DMSO stock solutions. After incubation for 72
h, the MTT solution was freshly prepared by dissolving 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT,
50 mg) in PBS (10 mL, both supplied in the MTT assay kit),
and 10 μL of this solution was added to each well. The cells
were incubated for an additional 4 h at 37 °C in a humid 5%
CO2 atmosphere for development to take place. The purple
formazan crystals produced were dissolved by addition of 2-
propanol (100 μL/well) containing HCl (0.04 M), and the
absorbance was measured at 570 nm with background
subtraction at 630 nm on a PerkinElmer EnSpire plate reader.
All assays were performed twice in triplicate.
Western Blot. Jurkat cells were cultivated in RPMI-1640
medium supplemented with 10% FBS and 1% penicillin/
streptomycin. At conﬂuency, cells were seeded in six-well plates
at a density of 500000 cells/well in 5 mL of culture medium.
After cultivation overnight at 37 °C in a humid 5% CO2
atmosphere, 500 μL of culture medium containing appropriate
concentrations of the compounds or the vehicle (DMSO) as a
control was added and incubated with various concentrations of
the inhibitor compounds at 37 °C for 24 h. The cells were then
washed, harvested, and lysed (lysis buﬀer BML-KI346-0020
from Enzo Life Sciences). Samples were then run on a
NuPAGE gel and transferred to a PVDF membrane using
standard techniques, and immunoblotting was performed using
a SNAP i.d. 2.0 protein detection system. The membrane was
blocked with 2.5% BSA in TBS buﬀer for 10 min and then
rinsed with TBS buﬀer (3 × 15 mL) and incubated with the
primary antibody (1:500 to 1:1000 dilution in TBS buﬀer) for
10 min. After being washed with TBS buﬀer (3 × 15 mL), the
membrane was incubated with the secondary antibody (1:5000
dilution in TBS buﬀer) for 10 min. Finally, the membrane was
rinsed with TBS buﬀer (3 × 15 mL) and developed with the
ECL Prime Western Blotting system (solutions A and B) with
standard techniques, and the images were recorded using a
Syngene PXi image recorder.
■ RESULTS
Binding Aﬃnity of Macrocycles. To assess the isolated
contribution to HDAC inhibition of the various macrocycles
found in cyclic nonribosomal natural products (Figure 1a), we
synthesized analogues containing an n-propyl group in place of
the extended zinc-binding side chain, 1a−11a (the altered side
chains are colored blue in Figure 2a). Although the general
alkyl group chain length was chosen on the basis of a previous
study of analogues of apicidin,22 we also addressed this by
synthesizing analogues of trapoxin B with varying lengths of the
alkyl group (4b−d). Brieﬂy, compounds 1a and 2a were
prepared by fragment coupling, introducing the ester bond
through a dimer building block common for both compounds
and achieving the ring closure via macrolactamization.29,30
Preparation of the thiazole−thiazoline fragment for synthesis of
the largazole analogue (2a) was adapted from syntheses
reported by the groups of Ganesan and co-workers31 and
Fairlie and co-workers32 (Supporting Figures S1 and S2).
The linear precursors of the cyclotetrapeptides were all
prepared by standard Fmoc solid-phase peptide synthesis, and
cyclization was achieved in solution at high dilutions
(Supporting Figure 3). With the compound collection in
hand, we screened for inhibition of the 11 zinc-dependent
HDAC enzymes at two inhibitor concentrations (Figure 2b).
Because cyclopeptide HDAC inhibitors are generally known to
be poor inhibitors of class IIa enzyme isoforms,24,25 we selected
compounds 3a, 10a, and 11a for testing against HDAC4, -5, -7,
and -9, which expectedly resulted in undetectable inhibition at
the highest concentration applied (Supporting Figure 4).
To more accurately compare the potencies of the various
scaﬀolds, we determined the binding aﬃnities against
recombinant HDAC1−3 (Figure 2c and Supporting Figure
5). As also indicated by the two-dose screening results, the
macrocycles of romidepsin (1a), trapoxins (3a and 4a), apicidin
A (10a), and azumamide (11a) were the most potent and the
n-propyl chain length proved to be superior to methyl (4b),
butyl (4c), and hexyl (4d). Surprisingly, considering the high
potencies of all selected natural products, signiﬁcant diﬀerences
were recorded for the isolated macrocycles. In particular, the
analogues of largazole, cyl-1 and -2, HC-toxin, and chlamydocin
exhibited drastic losses of activity compared to the activities of
the more potent scaﬀolds. cyl-1 and -2 are stereochemically
distinct from the more potent analogues, while HC-toxin and
chlamydocin distinguish themselves by not having an aromatic
residue at position AA1. On the basis of these ﬁndings, together
with Yoshida and co-workers’ seminal demonstration that cyclic
hydroxamic acid-containing peptides (“CHAPs”) exhibited
potent HDAC inhibition irrespective of the macrocyclic
scaﬀold,33 we hypothesize that these scaﬀolds require a strong
zinc-binding group to position them appropriately on the
protein surface (for further discussion of this issue, see the
section on structural considerations vide inf ra). Thus, we chose
the potent scaﬀolds of the trapoxins (3a and 4a, 1−2 μM) and
apicidin A (10a, 0.4−0.6 μM) as well as the signiﬁcantly less
active scaﬀold of cyl-2 (6a, 40−120 μM) for further
investigation through reintroduction of a series of zinc-binding
groups (Figure 2d).
HDAC Inhibition by Zinc-Binding Macrocyclic Com-
pounds and Prodrugs. We selected the zinc-binding groups
found in apicidin A (ethyl ketone) and azumamide C
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(carboxylate) as well as the corresponding ethyl and octyl
esters. The esters may act as potential prodrugs to enhance the
cell permeability of carboxylate-containing compounds, which
has been thought to hamper activity in cell-based assays.34
Finally, we included the hydroxamic acid to sample a broad
selection of zinc-binding groups and presumably enhance the
potencies of the two most promising scaﬀolds [4i and 10i
(Figure 2d)].
Because larger quantities of a common intermediate were
desired to achieve this further functionalization, we chose a
solution-phase approach to synthesize these analogues.
Surprisingly, we discovered that macrocycles containing
pipecolic acid were prone to ring opening. In particular, acidic
conditions applied to cleave the tert-butyl ester protection
group initially chosen proved to be detrimental to macrocycle
integrity through cleavage of the tertiary amide. For this reason,
we performed re-esteriﬁcation to enable postcyclization
deprotection of the carboxylate side chain under alkaline
conditions, which furnished the target compounds after
functionalization (Supporting Figures 6−10).
Generally, inhibitors based on the apicidin A structure
exhibited the highest potencies as expected on the basis of the
scaﬀold screens. However, not all combinations followed the
trends expected if we presumed an additive eﬀect of the
individual structural elements. Interestingly, cyl-2 analogues
containing zinc-binding groups exhibited leaps in potency larger
than those of other compounds, such that (S)-2-aminosuberic
acid (Asu)-containing cyl-2 (6f) and trapoxin analogues (3f and
4f) were equipotent (Ki values of 0.3−1.5 μM) contrary to their
norvaline analogues (Ki values of 1−2 μM vs >40 μM) (Figure
2 and Supporting Tables 1 and 4).
Furthermore, the (S)-2-amino-8-oxodecanoic acid (Aoda)-
containing and (S)-2-amino-8-(ethoxy)-8-oxooctanoic acid
[Asu(Et)]-containing cyl-2 analogues (6e and 6g, respectively)
were equipotent (Ki values of 8−25 nM) as opposed to other
macrocycles for which the ethyl ketones were at least an order
of magnitude more potent than ethyl esters, which was not
surprising on the basis of the high potency of ethyl ketone-
containing natural product apicidin (9 ).24 We found that the
intended prodrugs, containing Asu(Et) residues, were equi-
potent or slightly more potent than their carboxylate
Figure 3. Kinetic evaluation of inhibitors. (a) Michaelis−Menten plots and data ﬁtting for inhibition of HDAC1−3 by compounds 4a and 4e. (b)
Progression curves and data ﬁtting for the inhibition of HDAC1−3, -6, and -8 by compound 4i.
Biochemistry Article
DOI: 10.1021/acs.biochem.7b00725
Biochemistry 2017, 56, 5134−5146
5140
counterparts (Ki values of 5−10 nM vs values of 10−15 nM for
apicidin A analogues), whereas the octyl esters exhibited limited
inhibition, with Ki values higher than those of the
corresponding non-zinc-binding norvaline analogues. Finally,
we were surprised that hydroxamic acid-containing trapoxin B
(4i) and apicidin A (10i) did not exhibit signiﬁcant
enhancements in potency compared to those of their ethyl
ketone counterparts (0.4−1.7 nM), warranting further
evaluation of the mechanism of inhibition (Figure 2d; see
also Supporting Figures 11 and 12 and Supporting Tables 1 and
4).
Kinetic Investigation of Inhibitors. First, we performed a
kinetic evaluation of a selection of compounds to determine
whether they inhibit the HDACs by competing for the
substrate-binding site. Initial velocities (ν) were measured at
varying Kac substrate concentrations for diﬀerent inhibitor
concentrations, and the data were ﬁtted to the Michaelis−
Menten equation (Figure 3a and Supporting Figure 13).
Interestingly, all the investigated non-zinc-binding macrocycles
(1a, 4a, 10a, and 11a) exhibited noncompetitive (“mixed”)
inhibition as indicated by nonlinear relationships between both
Vmax,obsVmax
−1 and (Vmax/Km)obs(Vmax/Km)
−1 with respect to
inhibitor concentration (Figure 3a). However, examination of
the Kii values (uncompetitive inhibition constants) versus the
Kis values (competitive inhibition constants) showed that all
inhibition events were primarily competitive with respect to
substrate (Kis lower than Kii) (Supporting Table 2). Previously,
a non-zinc-binding macrocyclic inhibitor was determined to be
competitive with respect to substrate,22 but because a substrate
with diﬀerent binding kinetics was used in that study, together
with the observation of primarily competitive behavior of the
inhibitors in this study when comparing Kis and Kii values, we
have no reason to doubt this discrepancy. Carboxylate-
containing inhibitors 4f and 10f also exhibited “mixed”
inhibition; the more potent ethyl ketones [4e and apicidin A
(10)] were fully competitive, and the ethyl esters (4g and 10g)
exhibited mixed inhibition behavior (Figure 3a, Supporting
Figure 13, and Supporting Table 2). Surprisingly, the natural
compound azumamide C (11) also exhibited mixed inhibition,
although it potently inhibits HDAC1−3 at low nanomolar Ki
values (Supporting Tables 1, 2, and 4).
Next, we investigated the mode of inhibition of HDAC3
exhibited by natural products romidepsin (1), trapoxin A (3),
HC-toxin (7 ), apicidin (9 ), and apicidin A (10) as well as
members of the trapoxin B and apicidin A series of analogues
by performing continuous assays at varying inhibitor concen-
trations. As expected, n-propyl-, ethyl ketone-, and carboxylate-
containing analogues exhibited the standard fast-on/fast-oﬀ
mechanism (Supporting Figure 14). The epoxy ketone HC-
toxin (7 ) exhibited a slow, tight-binding mechanism against
HDAC1−3 but a fast-on/fast-oﬀ mechanism against HDAC6,
which is in agreement with previously reported investigations of
reversibility33,35 as well as a recent X-ray co-crystal structure of
HC-toxin and HDAC636 (Supporting Figure 14). More
surprisingly, both hydroxamate-containing compounds
[TpxBAsuha (4i) and ApiAAsuha (10i)] also exhibited a slow,
tight-binding kinetics against HDAC1−3 and -6 but not against
HDAC8 in the continuous assays (Figure 3b and Supporting
Figure 14).
Thus, the initially determined Ki values based on dose−
response experiments assuming steady-state kinetics are not an
appropriate measure of potency for these analogues. This also
means that previously reported IC50 values for TpxB
Asuha most
likely are misleading representations of potency and suggests
that other cyclic hydroxamic acid-containing peptides may
beneﬁt from re-evaluation of their mechanisms of inhibition.33
The Ki values calculated from the data ﬁtting of the continuous
assays were 20−40 pM against HDAC3-NCoR2, rendering
these compounds among the most potent hydroxamic acid-
containing HDAC inhibitors described to date (Supporting
Table 3). Furthermore, this provides an explanation for why
these analogues appeared to be equipotent to their ethyl ketone
homologues, contrary to expectation based on trends observed
upon comparison of these zinc-binding groups on simple
scaﬀolds.37
Finally, on the basis of our kinetic data, romidepsin also
proved to exhibit slow, tight binding, which has not been
previously acknowledged. This may create doubt about
previously reported potencies of this important compound, as
well, which is interesting because of its status as an approved
drug substance.
To further elucidate the binding kinetics and to investigate
whether the noncompetitive inhibitors should be considered
allosteric binders, we performed an exclusivity study of the
competitive ethyl ketone TpxBAoda (4e) and the non-
competitive n-propyl derivative TpxBNva (4a) by measuring
the steady-state kinetics of the inhibition of HDAC3 at varying
concentrations of the two inhibitors. The possible equilibria,
including the related dissociation constants, are shown in
Figure 4a. The interaction term (αAB) describes the degree of
interaction between the two inhibitors and reﬂects the potential
of mutual binding. Global ﬁtting of the data to the modiﬁed
Yonetani−Theorell equation27,28 (Figure 4b and Experimental
Figure 4. Kinetic analysis of exclusivity of inhibitor binding. (a)
Equilibria among enzyme species with two inhibitors, one competitive
(IA) and one noncompetitive (IB). (b) Dose-dependent inhibition of
HDAC3 by TpxBNva (4a) at various ﬁxed concentrations of TpxBAoda
(4e) and by TpxBAoda (4e) at various ﬁxed concentrations of TpxBNva
(4a), plotted as relative rates (νAB/ν0). (c) Reciprocal rates (ν0/νAB).
Biochemistry Article
DOI: 10.1021/acs.biochem.7b00725
Biochemistry 2017, 56, 5134−5146
5141
Procedures) gave an inﬁnite interaction term, corresponding to
mutually exclusive binding of the two inhibitors. This results in
parallel lines in the plot of reciprocal rates as a function of
either inhibitor (Figure 4c).28 While mutual exclusivity does
not exclude a potential allosteric anticooperative binding, the
observation supports the hypothesis of a common binding
pocket for the two inhibitors, as would be expected given the
structural similarity.
Structural Considerations. To rationalize the structure−
activity relationship (SAR) of the diﬀerent types of macrocyclic
scaﬀolds, we examined selected structures by NMR spectros-
copy and molecular modeling. The most striking loss of
potency upon removal of zinc-binding groups was observed for
cyl-1 and cyl-2 analogues. Because these compounds have a
diﬀerent stereochemical conﬁguration in the backbone
compared to the more potent compounds, apicidins and
trapoxins, we speculated that conformational diﬀerences might
explain the biochemical data. Using NMR spectroscopy, Rich
and co-workers determined the three-dimensional structure of
natural product WF-3161 in CDCl3.
38 WF-3161 is closely
related to cyl-2, diﬀering only by substitution of Ile with Leu
and removal of the p-OMe of the aromatic side chain, and our
NMR data obtained in CDCl3 for cyl-2 were in accordance with
the reported cis−trans−trans−trans (c−t−t−t) amide structure
of WF-3161.38 Thus, the amide bond between L-pipecolic acid
and isoleucine was in the cisoid conformation as indicated by an
∼2 ppm diﬀerence in chemical shift between the two Hε
protons of pipecolic acid, and the remaining amide bonds were
in the transoid conformation with the vicinal NH and Hα
protons being anti to one another as indicated by the Hα
chemical shifts as well as the large coupling constants [J > 9Hz
(Supporting Figure 16 and Supporting Table 5)]. The NMR
spectra of cyl-2Nva (6a) and cyl-2Aoda (6e) in DMSO-d6 were
also in accordance with the published structure, except for the
NH−Hα coupling constant of the Nva/Aoda residue, which
indicated ﬂipping of the amide to give a syn relationship
between these two protons. This may be explained by diﬀerent
tendencies for this amide bond NH to engage in hydrogen
bonding with the side chain carbonyl in cyl-2Aoda (6e) in
diﬀerent solvents, though such ﬂipping of an amide bond is not
expected to aﬀect the overall conformation of the macrocyclic
backbone signiﬁcantly.21 Interestingly, however, compounds 6f
and 6g both exhibited all trans-amide bonds in their major
conformations with all vicinal NH and Hα protons being anti in
both CDCl3 and DMSO-d6 (Supporting Figure 16 and
Supporting Table 5), indicating that conformational prefer-
ences of cyl-2 analogues are not only solvent-dependent but
also aﬀected by the choice of zinc-binding group. cis−trans
isomerization of tertiary amide bonds is known to be aﬀected
by local environment, stereoelectronic eﬀects, and the
solvent.39−41 However, it is not clear from this investigation
why the nature of the zinc-binding group appears to aﬀect this
equilibrium for cyl-2 analogues, because these side chains are
highly ﬂexible in solution.21
Nevertheless, overlaying the backbone of the lowest-energy
conformation of cyl-2, which is in agreement with our NMR
data for the norvaline analogue (6a), with previously
determined structures of apicidin42,43 revealed diﬀerences in
the display of the amide protons of Nva/Aoda and D-Tyr(Me)
residues as well as the Cα−Cβ vector of D-Tyr(Me) (Figure
Figure 5. Three-dimensional conformations of macrocycles and docking poses. (a) Backbone of apicidin in the c−t−t−t conformation determined
by X-ray crystallography42 (cyan, X-ray) overlaid with lowest-energy structures of apicidin in the all-trans conformation (purple) and cyl-2 in the c−
t−t−t conformation (green), which are in accordance with our NMR data and match previously reported NMR structures of the predominant
conformations in solution.38 (b) Backbone of azumamide A determined by NMR spectroscopy34 (magenta) overlaid with the two apicidin
conformations mentioned above (cyan and purple). (c) Docking of apicidinAsuha to the HDAC3:SMRT-DAD complex (PDB entry 4A69) depicted
as a gray surface with the Asp-93 residue colored red. (d) Docking of cyl-2Asuha to the HDAC3:SMRT-DAD complex (PDB entry 4A69) depicted as
a gray surface with the Asp-93 residue colored red.
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5a). The Ile-NH, Ile side chain, and zinc-binding side chain
were all positioned like those in apicidin. On the other hand, all
features found to be important for the inhibition of HDAC3 by
azumamide C via the application of molecular docking34
overlaid well with the apicidin conformations, although
azumamides contain three D-amino acids and a β-amino acid
to give a 13-membered ring macrocycle (Figure 5b). The Aoda-
NH was positioned like the β2-methyl group of azumamide;
however, it is likely that this NH group would be able to
accomplish an important coordination to Asp-93 in HDAC3
instead of D-Val-NH in azumamides31 (Figure 5b).
The NMR spectra recorded for the trapoxin B analogues
were also in accordance with the predominant all-trans
conformation of apicidin, which is not surprising given the
similar stereochemistry of all residues in the two molecules
(Supporting Figures 17 and 18 and Supporting Tables 6 and 7).
Thus, the diﬀerences and similarities in three-dimensional
structures determined by NMR correspond well with the
HDAC inhibition data that showed apicidins, trapoxins, and
azumamides exhibited potencies in the same range, while cyl-1
and cyl-2 analogues were signiﬁcantly less potent.
Finally, we computationally docked selected compounds into
the X-ray crystal structures of HDAC2 (PDB entry 4LY1)44
and the HDAC3:SMRT-DAD complex (PDB entry 4A69)45 to
evaluate the potential signiﬁcance of these structural diﬀerences
further. First, norvaline analogues of trapoxin B, apicidin, and
cyl-2 were attempted, but presumably because of the low
aﬃnities, these macrocycles provided unexpected docking poses
by projecting the aromatic side chains toward the active site
channel (Supporting Figure 19). This resulted in unstable poses
during the subsequent MD simulations, in which only the
norvaline analogue of apicidin stayed bound to HDAC2
throughout the entire simulation time. To probe the eﬀects
of the diﬀerences found in the conformations of macrocycles by
NMR spectroscopy as described above, we then docked
hydroxamic acid-containing versions of apicidin and cyl-2,33
which chelated to the Zn2+ ion as expected (Figure 5c,d). The
pose of the apicidin analogue (Figure 5c) involved hydrogen
bonding between backbone amide NH groups and the
carboxylate side chain of the Asp-93 residue as envisioned on
the basis of previous docking studies with azumamides.34 This
was not the case for the cyl-2 analogue, which docked to a
completely diﬀerent region of the enzyme surface (Figure 5d).
However, both analogues stayed bound to both HDAC2 and -3
throughout the full MD simulation times. Importantly, this is in
agreement with both our predictions based on the conforma-
tional investigation, indicating that the cyl-2 macrocycle did not
possess the structural features necessary to bind to the
important Asp-93 residue, and the similar IC50 values of
hydroxamic acid-containing analogues provided here and
previously.30 This underscores the utility of NMR spectroscopy
combined with molecular modeling to rationalize compound
potencies and thus to provide insight for the future design of
potent HDAC inhibitors.
Cell Growth Inhibition and Western Blot. With our
series of inhibitors, exhibiting a broad range of potencies and
covering a variety of functional groups, we assessed their ability
to inhibit the growth of cancer cells in culture. We chose a
panel of ﬁve cell lines, including nonmalignant HEK293 cells,
solid tumor HeLa and MCF-7 cells, and leukemic cell lines
Jurkat and HL-60. In general, the cell-based assays recapitulated
the potencies recorded against recombinant enzymes. The
tested non-zinc-binding analogues (1a, 3a, 4a, and 10a) and
carboxylate-containing compounds (4f and 10f) exhibited low
to undetectable activities, whereas the ethyl ester analogue on
the most potent scaﬀold of apicidin A (10g) exhibited
potencies similar to those observed for the marketed drug
compound SAHA (also known as vorinostat or Zolinza)46
(Figure 6a). On the basis of these data, however, it is not clear
whether ethyl ester compound 10g exerts its activity through
the intended prodrug mechanism, because the octyl ester
analogues (4h and 10h) were generally inactive. The ethyl
ketone-containing compounds (3e, 4e, 6e, 9 , and 10) exhibited
potencies similar to or higher than those of SAHA, and in the
case of apicidin A (10), inhibition of HeLa and Jurkat cells was
even comparable to or better than that of the drug romidepsin
(1). Interestingly, the selectivity indices of apicidin A (10) for
HeLa, Jurkat, and HL-60 cells over the nonmalignant HEK293
cells were higher than those of both marketed drugs (Figure
6a). The hydroxamic acid-containing cyclopeptide based on
apicidin A (10i) was slightly more potent than the previously
reported trapoxin B analogue (4i),33 rivaling the potencies of
romidepsin (1), and the two epoxy ketone-containing natural
products [trapoxin A (3) and HC-toxin (7 )] were also highly
active across the entire panel of cell lines. None of these highly
potent compounds, however, exhibited selectivity for malignant
cells over HEK293 cells (Figure 6a).
To investigate whether our compounds aﬀected the
epigenetic state in cells, we also incubated Jurkat cells with a
selection of compounds at varying concentrations and
performed Western blots to monitor the degree of protein
acetylation (Figure 6b). Acetylation of histones H3 and H4 as
well as α-tubulin was tested, and β-actin was included as a
Figure 6. Compound activities in cells. (a) Growth inhibition of
HEK293, HeLa, MCF-7, Jurkat, and HL-60 cells. For GI50 values with
standard deviations and dose−response curves, see Supporting Table 8
and Supporting Figure 20. (b) Levels of histone and tubulin
acetylation in Jurkat cells visualized by Western blot upon treatment
with selected inhibitors at 1 or 10 μM. For pictures of the full blots as
well as Coomassie-stained gel, see Supporting Figure 21.
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reference, indicating equal levels of protein in each lane. In
agreement with the HDAC inhibition proﬁling, the most potent
compounds (i.e., ethyl ester 4g, ethyl ketone 4e, and
hydroxamic acid 4i) caused signiﬁcant degrees of hyper-
acetylation of both histones 3 and 4. Highly potent compound
4i was able to do so at doses of both 1 and 10 μM and, in
agreement with its potent HDAC6 inhibition, also caused
hyperacetylation of α-tubulin (Figure 6b). Though the β-actin
loading control bands were slightly weaker for these
preparations, the eﬀect on acetylation was strong, clearly
showing the expected eﬀect of these highly potent compounds.
Furthermore, total protein across the various samples did not
appear to vary signiﬁcantly on the basis of Coomassie staining
(Supporting Figure 21). Finally, it was interesting that the
norvaline compound 4a, which was not cytotoxic at the highest
concentration tested, gave rise to weak bands in the acetylated
H3 and H4 immunoblots, indicating class I HDAC inhibition in
cells.
■ DISCUSSION
Macrocyclic, peptide-based chemotypes that potently inhibit
class I HDAC1−3 have been isolated from a wide variety of
organisms.20 Nature appears to have produced these com-
pounds as part of the innate defense systems of the hosts, and
most of them exhibit cytotoxic or antiparasitic activity in line
with this hypothesis. One such compound, romidepsin (1), has
been approved for the treatment of cutaneous T-cell
lymphoma, highlighting the importance of these natural
products. However, while oﬀ-target eﬀects and some degree
of toxicity toward patient cells and tissues may be accepted for
cancer treatment, the inherent toxicity of these macrocyclic
natural products may not be tolerated for other indications.
Thus, taming these potent compounds to target HDAC
enzymes for other biomedical applications may be possible by
chemical modiﬁcation of the parent structures. Here, we
selected a series of 10 diﬀerent natural compounds and
synthesized analogues devoid of the various zinc-binding
groups, installed by Nature, to gain insight into the contribution
to HDAC binding by the macrocyclic cores. Inhibition of
recombinant HDAC enzymes showed that the macrocycles of
the highly potent natural products cyl-1, cyl-2, HC-toxin, and
largazole did not exhibit signiﬁcant aﬃnities for the enzyme
surfaces, indicating that these are not ideal candidates for
optimization because they rely heavily on a strong zinc-binding
group. Largazole, a previously reported analogue, containing a
hydrocarbon side chain without the zinc-binding thiol, also
exhibited low potency.47 However, the inspiring work on
modiﬁcation of natural macrocycles by Yoshida and co-workers,
examining cyclic hydroxamic acid-containing peptides, did not
reveal this, presumably because of the introduction of the
strongly zinc chelating hydroxamate.33 Our computational
study also provides support of this theory by indicating the high
aﬃnity of both cyl-2 and apicidin hydroxamates that block the
active site throughout the course of our MD simulations. The
less potent norvaline analogues docked in diﬀerent poses and
were generally not able to stay bound during MD simulations,
which we believe to be in agreement with the noncompetitive
(mixed) inhibition and mutual exclusivity observed in the
kinetic studies.
Upon reintroduction of less potent zinc binders such as
carboxylate, ethyl ester, or ethyl ketone, on the other hand, the
lessons learned from the non-zinc-binding series were
recapitulated with signiﬁcantly more potent compounds arising
from refunctionalization of apicidin A and the trapoxins. This
was gratifying as these results agreed with the structural
rationale based on the macrocyclic conformational evaluation
by NMR. Taken together, the results demonstrate that the
contributions to binding from the macrocycle and zinc-binding
group cannot be considered additive, which was a surprise to
us, and a highly important feature to consider when designing
novel inhibitors.
Another surprise arose from the kinetic investigation of
inhibition by continuous assays, which showed that the tested
hydroxamic acid-containing macrocycles exhibited slow, tight-
binding mechanisms. To the best of our knowledge, this is the
ﬁrst demonstration of hydroxamic acid-containing HDAC
inhibitors that exhibit long residence times. In most cases, the
oﬀ rates were too slow to be estimated from this experimental
setup and the behavior was kinetically similar to that of the
irreversible epoxy ketone-containing inhibitors HC-toxin and
trapoxin A. The examples in which Ki values could be extracted
from the data furnished 20−40 pM aﬃnities for HDAC3,
indicating that previous determinations of hydroxamic acid-
containing macrocycles by traditional dose−response experi-
ments21,33,48 do not reﬂect the actual potencies of these
compounds. The ethyl ketone compounds behaved as more
traditional fast-on/fast-oﬀ inhibitors, now enabling the design
of HDAC inhibitors based on not only aﬃnity but also binding
kinetics, which could prove to be valuable for novel probes. As
spearheaded by Copeland and co-workers, the drug−target
residence time has become an important parameter to
consider,49,50 and very recently, a study reported the kinetic
requirements of HDAC inhibitors for enhancing progranulin
expression.51 Thus, the collective information presented herein
delivers important reﬁnements to the model for how to design
HDAC inhibitors in the future.
Finally, we also provide proﬁling of growth inhibition of a
series of immortalized cell lines and show by Western blotting
that the compounds furnish the eﬀects on histone and α-
tubulin acetylation levels in Jurkat cells that would be expected
on the basis of the in vitro HDAC inhibition proﬁles.
Importantly, the approved substance romidepsin was shown
to exhibit an unexpected mechanism of inhibition, which
should be investigated in further detail. The detailed
mechanistic insight aﬀorded by this study should improve the
interpretation of biological data arising from use of HDAC
inhibitors as probes and potential medicines. This will also
serve as a basis upon which to select probes in future studies. In
addition to potency and subtype selectivity, diﬀerent kinetic
proﬁles may now be taken into account.
■ ASSOCIATED CONTENT
*S Supporting Information
The Supporting Information is available free of charge on the
ACS Publications website at DOI: 10.1021/acs.bio-
chem.7b00725.
Supporting ﬁgures, schemes, and tables, experimental
procedures, characterization data, and copies of 1H and
13C NMR spectra (PDF)
■ AUTHOR INFORMATION
Corresponding Author
*E-mail: cao@sund.ku.dk.
ORCID
Peter Fristrup: 0000-0001-7175-3796
Biochemistry Article
DOI: 10.1021/acs.biochem.7b00725
Biochemistry 2017, 56, 5134−5146
5144
Christian A. Olsen: 0000-0002-2953-8942
Funding
We gratefully acknowledge ﬁnancial support from the
University of Copenhagen, the Lundbeck Foundation (Group
Leader Fellowship R52-2010-5054 to C.A.O. and Grant R141-
2013-13656 to P.F.), the Carlsberg Foundation (2013-01-0333
and CF15-011 to C.A.O.), the Novo Nordisk Foundation
(NNF15OC0017334 to C.A.O.), and the European Research
Council (ERC-CoG-725172-SIRFUNCT to C.A.O.).
Notes
The authors declare no competing ﬁnancial interest.
■ ACKNOWLEDGMENTS
We thank Nima Rajabi for synthesis of the Cbz-Asu(tBu)-OH
building block and Jens Engel-Andreasen for synthesis of the
Fmoc-Aoda-OH building block, Jonas S. Harild and Julie L. H.
Madsen for assistance with Western blots, Janne M. Colding for
assistance with the cell culture, and Stephan A. Pless for
donation of the HEK293 cell line. We thank Jens Ø. Duus and
Günther H. J. Peters for fruitful discussions regarding molecular
modeling and NMR spectroscopy.
■ REFERENCES
(1) Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M.,
Walther, T. C., Olsen, J. V., and Mann, M. (2009) Lysine acetylation
targets protein complexes and co-regulates major cellular functions.
Science 325, 834−840.
(2) Schölz, C., Weinert, B. T., Wagner, S. A., Beli, P., Miyake, Y., Qi,
J., Jensen, L. J., Streicher, W., McCarthy, A. R., Westwood, N. J., Lain,
S., Cox, J., Matthias, P., Mann, M., Bradner, J. E., and Choudhary, C.
(2015) Acetylation site specificities of lysine deacetylase inhibitors in
human cells. Nat. Biotechnol. 33, 415−423.
(3) Haberland, M., Montgomery, R. L., and Olson, E. N. (2009) The
many roles of histone deacetylases in development and physiology:
implications for disease and therapy. Nat. Rev. Genet. 10, 32−42.
(4) Houtkooper, R. H., Pirinen, E., and Auwerx, J. (2012) Sirtuins as
regulators of metabolism and healthspan. Nat. Rev. Mol. Cell Biol. 13,
225−238.
(5) Gregoretti, I. V., Lee, Y. M., and Goodson, H. V. (2004)
Molecular evolution of the histone deacetylase family: Functional
implications of phylogenetic analysis. J. Mol. Biol. 338, 17−31.
(6) Frye, R. A. (2000) Phylogenetic classification of prokaryotic and
eukaryotic Sir2-like proteins. Biochem. Biophys. Res. Commun. 273,
793−798.
(7) West, A. C., and Johnstone, R. W. (2014) New and emerging
HDAC inhibitors for cancer treatment. J. Clin. Invest. 124, 30−39.
(8) Falkenberg, K. J., and Johnstone, R. W. (2014) Histone
deacetylases and their inhibitors in cancer, neurological diseases and
immune disorders. Nat. Rev. Drug Discovery 13, 673−691.
(9) Kazantsev, A. G., and Thompson, L. M. (2008) Therapeutic
application of histone deacetylase inhibitors for central nervous system
disorders. Nat. Rev. Drug Discovery 7, 854−868.
(10) Guan, J. S., Haggarty, S. J., Giacometti, E., Dannenberg, J. H.,
Joseph, N., Gao, J., Nieland, T. J., Zhou, Y., Wang, X., Mazitschek, R.,
Bradner, J. E., DePinho, R. A., Jaenisch, R., and Tsai, L. H. (2009)
HDAC2 negatively regulates memory formation and synaptic
plasticity. Nature 459, 55−60.
(11) Graf̈f, J., Rei, D., Guan, J. S., Wang, W. Y., Seo, J., Hennig, K. M.,
Nieland, T. J., Fass, D. M., Kao, P. F., Kahn, M., Su, S. C., Samiei, A.,
Joseph, N., Haggarty, S. J., Delalle, I., and Tsai, L. H. (2012) An
epigenetic blockade of cognitive functions in the neurodegenerating
brain. Nature 483, 222−226.
(12) Chen, B., and Cepko, C. L. (2009) HDAC4 regulates neuronal
survival in normal and diseased retinas. Science 323, 256−259.
(13) Sabari, B. R., Zhang, D., Allis, C. D., and Zhao, Y. (2017)
Metabolic regulation of gene expression through histone acylations.
Nat. Rev. Mol. Cell Biol. 18, 90−101.
(14) Wightman, F., Ellenberg, P., Churchill, M., and Lewin, S. R.
(2012) HDAC inhibitors in HIV. Immunol. Cell Biol. 90, 47−54.
(15) Archin, N. M., Liberty, A. L., Kashuba, A. D., Choudhary, S. K.,
Kuruc, J. D., Crooks, A. M., Parker, D. C., Anderson, E. M., Kearney,
M. F., Strain, M. C., Richman, D. D., Hudgens, M. G., Bosch, R. J.,
Coffin, J. M., Eron, J. J., Hazuda, D. J., and Margolis, D. M. (2012)
Administration of vorinostat disrupts HIV-1 latency in patients on
antiretroviral therapy. Nature 487, 482−485.
(16) Du, J., Zhou, Y., Su, X., Yu, J. J., Khan, S., Jiang, H., Kim, J.,
Woo, J., Kim, J. H., Choi, B. H., He, B., Chen, W., Zhang, S., Cerione,
R. A., Auwerx, J., Hao, Q., and Lin, H. (2011) Sirt5 is a NAD-
dependent protein lysine demalonylase and desuccinylase. Science 334,
806−809.
(17) Tan, M., Peng, C., Anderson, K. A., Chhoy, P., Xie, Z., Dai, L.,
Park, J., Chen, Y., Huang, H., Zhang, Y., Ro, J., Wagner, G. R., Green,
M. F., Madsen, A. S., Schmiesing, J., Peterson, B. S., Xu, G., Ilkayeva,
O. R., Muehlbauer, M. J., Braulke, T., Mühlhausen, C., Backos, D. S.,
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Supporting Figure 1. Synthesis of romidepsin analog (RomiAla,Hha, 1a). Reagents and conditions (a): i) Boc-
Val-OH, DIC, DMAP, CH2Cl2. ii) Pd/C (10 wt%), H2, EtOH, then pentafluorophenyl trifluoroacetate, pyridine, 
DMF. (b): iii) TFA, CH2Cl2, then Boc-D-Ala-OH, HATU, iPr2EtN, CH2Cl2. iv) DMAP, Et3N, MsCl, CH2Cl2. v) 
DABCO, CH2Cl2. vi) Boc-D-Val-OH, HATU, iPr2EtN, CH2Cl2. vii) LiOH, THF, H2O, then TFA, CH2Cl2. viii) S3, 
Et3N, CH2Cl2. ix) TFA, CH2Cl2, then HATU, iPr2NEt, DMF. 
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Supporting Figure 2. Synthesis of largazole analog (LgzHha, 2a). Reagents and conditions: i) Lawesson 
reagent, CH2Cl2. ii) Methyl bromopyruvate, DME, KHCO3, TFAA, 2,6-lutidine. iii) NH3 (aq.), MeOH. iv) Oxalyl 
chloride, CH2Cl2, DMSO, Et3N. v) (R)-α-methylcysteine, NaHCO3, MeOH, phosphate buffer. vi) HBr, 
CH3CO2H, then S3, Et3N, CH2Cl2. vii) TFA, CH2Cl2, then HATU, iPr2EtN, DMF. 
 
 
 
 
 
 
 
 
 
Supporting Figure 3. Synthesis of macrocyclic norvaline analogs (3a-10a). Reagents and conditions: i) 
Fmoc-Nva-OH, iPr2NEt, CH2Cl2. ii) Piperidine, DMF, then Fmoc-Aa-OH, 2,6-lutidine, HATU, DMF. iii) 
Piperidine, DMF, then Fmoc-Aa-OH, 2,6-lutidine, HATU, DMF. iv) piperidine, DMF, then TFA, CH2Cl2. v) 
HATU, iPr2NEt, DMF. 
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Supporting Figure 4. Inhibition of HDAC1–11 at 10 µM inhibitor concentration. 
 
 
Supporting Figure 5. Dose–response curves of macrocycles with the zinc-binding groups excised against 
HDAC1–3.   
HD
AC
1
HD
AC
2
HD
AC
3*
HD
AC
8
HD
AC
4
HD
AC
5
HD
AC
7
HD
AC
9
HD
AC
6
HD
AC
10
HD
AC
11
0
50
100
In
hib
itio
n 
(%
)
11a (AzuCAmha)
HD
AC
1
HD
AC
2
HD
AC
3*
HD
AC
8
HD
AC
4
HD
AC
5
HD
AC
7
HD
AC
9
HD
AC
6
HD
AC
10
HD
AC
11
10a (ApiANva)
HD
AC
1
HD
AC
2
HD
AC
3*
HD
AC
8
HD
AC
4
HD
AC
5
HD
AC
7
HD
AC
9
HD
AC
6
HD
AC
10
HD
AC
11
8a (ChlamNva)
HD
AC
1
HD
AC
2
HD
AC
3*
HD
AC
8
HD
AC
4
HD
AC
5
HD
AC
7
HD
AC
9
HD
AC
6
HD
AC
10
HD
AC
11
7a (HCtxNva)
HD
AC
1
HD
AC
2
HD
AC
3*
HD
AC
8
HD
AC
4
HD
AC
5
HD
AC
7
HD
AC
9
HD
AC
6
HD
AC
10
HD
AC
11
0
50
100
In
hib
itio
n 
(%
)
6a (cyl-2Nva)
HD
AC
1
HD
AC
2
HD
AC
3*
HD
AC
8
HD
AC
4
HD
AC
5
HD
AC
7
HD
AC
9
HD
AC
6
HD
AC
10
HD
AC
11
5a (cyl-1Nva)
HD
AC
1
HD
AC
2
HD
AC
3*
HD
AC
8
HD
AC
4
HD
AC
5
HD
AC
7
HD
AC
9
HD
AC
6
HD
AC
10
HD
AC
11
4d (TpxBAoa)
HD
AC
1
HD
AC
2
HD
AC
3*
HD
AC
8
HD
AC
4
HD
AC
5
HD
AC
7
HD
AC
9
HD
AC
6
HD
AC
10
HD
AC
11
4c (TpxBNle)
HD
AC
1
HD
AC
2
HD
AC
3*
HD
AC
8
HD
AC
4
HD
AC
5
HD
AC
7
HD
AC
9
HD
AC
6
HD
AC
10
HD
AC
11
0
50
100
In
hib
itio
n 
(%
)
4b (TpxBAla)
HD
AC
1
HD
AC
2
HD
AC
3*
HD
AC
8
HD
AC
4
HD
AC
5
HD
AC
7
HD
AC
9
HD
AC
6
HD
AC
10
HD
AC
11
4a (TpxBNva)
HD
AC
1
HD
AC
2
HD
AC
3*
HD
AC
8
HD
AC
4
HD
AC
5
HD
AC
7
HD
AC
9
HD
AC
6
HD
AC
10
HD
AC
11
3a (TpxANva)
HD
AC
1
HD
AC
2
HD
AC
3*
HD
AC
8
HD
AC
4
HD
AC
5
HD
AC
7
HD
AC
9
HD
AC
6
HD
AC
10
HD
AC
11
2a (LgzHha)
HD
AC
1
HD
AC
2
HD
AC
3*
HD
AC
8
HD
AC
4
HD
AC
5
HD
AC
7
HD
AC
9
HD
AC
6
HD
AC
10
HD
AC
11
0
50
100
In
hib
itio
n 
(%
)
1a (RomiAla,Hha)
3a (TpxANva)
4a (TpxBNva)
10a (ApiANva)
5a (cyl-1Nva)
6a (cyl-2Nva)
8a (ChlamNva)
11a (AzuCAmha)
1a (RomiAla,Hha)HDAC3*
-9 -8 -7 -6 -5 -4 -3 -2
log [compound (M)]
HDAC2
-9 -8 -7 -6 -5 -4 -3 -2
log [compound (M)]
HDAC1
-9 -8 -7 -6 -5 -4 -3 -2
0
50
100
log [compound (M)]
re
sid
ua
l H
DA
C 
ac
tiv
ity
 (%
)
  S6 
 
Supporting Figure 6. Synthesis of trapoxin A analogs (TpxAAoda (3e), TpxAAsu (3f), and TpxAAsu(Et) (3g)). 
Reagents and conditions: i) Fmoc-Aa-OH, 2,6-lutidine, HATU, DMF, then piperidine, DMF. ii) TFA, CH2Cl2, 
then HATU, iPr2NEt, DMF. iii) Boc-Phe-OH, PyBOP, N-ethylmorpholine, DMF. iv) TFA, CH2Cl2, then Boc-
Phe-OH, HATU, 2,6-lutidine, DMF. v) TFA, CH2Cl2, then Cbz-Asu(tBu)-OH, HATU, 2,6-lutidine, DMF. vi) 
TFA, CH2Cl2, then EDC, DMAP, DMF. vii) H2, Pd/C, MeOH, then HATU, iPr2NEt, DMF. viii) LiOH, H2O, THF. 
